MEN1
MCID: MLT156
MIFTS: 72

Multiple Endocrine Neoplasia, Type I (MEN1)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Multiple Endocrine Neoplasia, Type I

MalaCards integrated aliases for Multiple Endocrine Neoplasia, Type I:

Name: Multiple Endocrine Neoplasia, Type I 57
Multiple Endocrine Neoplasia Type 1 11 24 19 58 75 53 43 14 71
Wermer Syndrome 57 11 24 19 58
Men1 57 24 19 58 73
Multiple Endocrine Neoplasia, Type 1 28 5
Multiple Endocrine Neoplasia 1 57 12
Familial Multiple Endocrine Neoplasia Type I 73
Neoplasia, Endocrine, Multiple, Type 1 38
Endocrine Adenomatosis, Multiple 57
Multiple Endocrine Adenomatosis 24
Endocrine Adenomatosis Multiple 19
Multiple Endocrine Neoplasia 71
Wermer's Syndrome 11
Men1 Syndrome 24
Men Type I 11
Men I 57
Mea I 57
Men 1 19

Characteristics:


Inheritance:

Multiple Endocrine Neoplasia, Type I: Autosomal dominant 57
Multiple Endocrine Neoplasia Type 1: Autosomal dominant 58

Prevelance:

Multiple Endocrine Neoplasia Type 1: 1-9/100000 (Europe) 58

Age Of Onset:

Multiple Endocrine Neoplasia Type 1: All ages 58

Age Of Death:

Multiple Endocrine Neoplasia Type 1: adult 58

GeneReviews:

24
Penetrance The age-related penetrance for all clinical features surpasses 50% by age 20 years and 95% by age 40 years [brandi et al 2021].

Classifications:

Orphanet: 58  
Rare gastroenterological diseases
Rare endocrine diseases


Summaries for Multiple Endocrine Neoplasia, Type I

GARD: 19 Multiple endocrine neoplasia, type 1 (MEN1) causes the growth of tumors in both the endocrine system (the body's network of hormone-producing glands) and non-endocrine system. Symptoms of MEN1 include tumors of the parathyroid gland, the pituitary gland, and the pancreas, although other glands may be involved as well. These tumors are often "functional" and secrete excess hormones, which can cause a variety of health problems. Additional signs and symptoms of MEN1 may depend on the type of tumor present and which hormones are being secreted. The most common symptoms are cause by an overactive parathyroid gland and may include kidney stones; thinning of bones; nausea and vomiting; high blood pressure (hypertension); weakness; and fatigue. MEN1 is caused by genetic variants in the MEN1 gene and is inherited in an autosomal dominant pattern. It is diagnosed based on the presence of two or more endocrine tumors in one person. The results of genetic testing can help confirm the diagnosis.

MalaCards based summary: Multiple Endocrine Neoplasia, Type I, also known as multiple endocrine neoplasia type 1, is related to gastric neuroendocrine neoplasm and insulinoma, and has symptoms including diarrhea An important gene associated with Multiple Endocrine Neoplasia, Type I is MEN1 (Menin 1), and among its related pathways/superpathways are Prolactin Signaling and Signal Transduction. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, pancreas and thyroid, and related phenotypes are hypercalcemia and primary hyperparathyroidism

OMIM®: 57 Multiple endocrine neoplasia type I (MEN1) is an autosomal dominant disorder characterized by varying combinations of tumors of parathyroids, pancreatic islets, duodenal endocrine cells, and the anterior pituitary, with 94% penetrance by age 50. Less commonly associated tumors include foregut carcinoids, lipomas, angiofibromas, thyroid adenomas, adrenocortical adenomas, angiomyolipomas, and spinal cord ependymomas. Except for gastrinomas, most of the tumors are nonmetastasizing, but many can create striking clinical effects because of the secretion of endocrine substances such as gastrin, insulin, parathyroid hormone, prolactin, growth hormone, glucagon, or adrenocorticotropic hormone (summary by Chandrasekharappa et al., 1997). Familial isolated hyperparathyroidism (see 145000) occasionally results from the incomplete expression of MEN1 (summary by Simonds et al., 2004). (131100) (Updated 24-Oct-2022)

UniProtKB/Swiss-Prot: 73 Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

Orphanet: 58 A rare inherited cancer syndrome, characterized by the development of multiple neuroendocrine tumors of the parathyroids, gastro-entero-pancreatic tract, and anterior pituitary gland, and less commonly the adrenal cortical gland, thymus and bronchi, with other non-endocrine tumors in some patients.

Disease Ontology: 11 A multiple endocrine neoplasia that has material basis in a mutation in the MEN1 tumor suppressor gene and is characterized by over active endocrine glands frequently involving tumors of the parathyroid glands, the pituitary gland, and the pancreas.

Wikipedia: 75 Multiple endocrine neoplasia type 1 (MEN-1) is one of a group of disorders, the multiple endocrine... more...

GeneReviews: NBK1538

Related Diseases for Multiple Endocrine Neoplasia, Type I

Diseases in the Multiple Endocrine Neoplasia family:

Multiple Endocrine Neoplasia, Type I Multiple Endocrine Neoplasia, Type Iib
Multiple Endocrine Neoplasia, Type Iia Multiple Endocrine Neoplasia, Type Iv

Diseases related to Multiple Endocrine Neoplasia, Type I via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 616, show less)
# Related Disease Score Top Affiliating Genes
1 gastric neuroendocrine neoplasm 32.7 SST MEN1 GAST CHGA
2 insulinoma 32.7 SST SCT MEN1 GAST CHGA CASR
3 multiple endocrine neoplasia, type iia 32.5 SDHD RET MEN1 CDKN1B CDC73
4 hyperparathyroidism 1 32.4 MEN1 CDC73
5 multiple endocrine neoplasia, type iib 32.4 SDHD RET MEN1 CDKN1B
6 acth-secreting pituitary adenoma 32.4 SST PRL PRKAR1A MEN1
7 multiple endocrine neoplasia, type iv 32.3 RET PRKAR1A MEN1 GNAS CDKN2C CDKN1B
8 secondary hyperparathyroidism 32.2 PRKAR1A MEN1 CASR
9 paraganglioma 32.1 SST SDHD RET MEN1 CHGA
10 atrophic gastritis 32.0 SST SCT MEN1 GAST CHGA
11 hyperparathyroidism 2 with jaw tumors 32.0 RET MEN1 CDC73 CASR
12 neurofibromatosis, type i 32.0 SST SDHD RET MEN1
13 parathyroid gland disease 31.9 RET PRL MEN1 GAST CDC73 CASR
14 von hippel-lindau syndrome 31.9 SST SDHD RET MEN1 GAST CHGA
15 thyroid gland cancer 31.9 SST SDHD RET MEN1 GAST CHGA
16 pancreatic endocrine carcinoma 31.9 SST MEN1 GAST CHGA
17 thyroid gland medullary carcinoma 31.9 SST RET MEN1 GAST CHGA
18 acth-independent macronodular adrenal hyperplasia 31.9 PRKAR1A MEN1 GNAS
19 adrenal cortical carcinoma 31.9 PRKAR1A MEN1 GNAS CHGA
20 pulmonary neuroendocrine tumor 31.9 SST MEN1 CHGA
21 skin lipoma 31.8 RET MEN1 GAST
22 gastritis, familial giant hypertrophic 31.8 SST MEN1 GAST
23 hypocalciuric hypercalcemia, familial, type i 31.8 MEN1 CDKN1B CDC73 CASR
24 large cell neuroendocrine carcinoma 31.8 SST MEN1 CHGA
25 somatostatinoma 31.8 SST MEN1 GAST CHGA
26 small intestine neuroendocrine neoplasm 31.8 SST MEN1 CHGA CDKN1B
27 non-functioning pancreatic endocrine tumor 31.8 SST MEN1 GAST CHGA
28 small intestine benign neoplasm 31.8 SST MEN1 CHGA CDKN1B
29 duodenal gastrinoma 31.8 SST SCT MEN1 GAST CHGA
30 gastrointestinal neuroendocrine benign tumor 31.8 SST MEN1 GAST CHGA
31 lung large cell carcinoma 31.8 SST MEN1 CHGA
32 zollinger-ellison syndrome 31.8 SST SCT MEN1 GAST CHGA
33 gastrointestinal neuroendocrine tumor 31.8 SST MEN1 GAST CHGA
34 pituitary infarct 31.8 SST PRL MEN1
35 multiple mucosal neuroma 31.8 RET MEN1
36 pancreatic serous cystadenoma 31.8 MEN1 CHGA
37 gastrointestinal stromal tumor 31.8 SST SDHD RET MEN1 CHGA
38 serotonin syndrome 31.8 SST MEN1 GAST CHGA
39 hypocalciuric hypercalcemia, familial, type ii 31.8 MEN1 CDC73 CASR
40 pancreatic somatostatinoma 31.8 SST SCT MEN1 GAST
41 ossifying fibroma 31.8 MEN1 GNAS CDC73
42 hormone producing pituitary cancer 31.8 SST PRL PRKAR1A MEN1 GNAS
43 dicer1 syndrome 31.8 PRKAR1A MEN1 GNAS
44 sublingual gland cancer 31.8 RET MEN1
45 mccune-albright syndrome 31.8 SST PRL PRKAR1A MEN1 GNAS
46 gastrointestinal system benign neoplasm 31.8 SST MEN1 GAST CHGA
47 paraganglioma and gastric stromal sarcoma 31.8 SDHD RET MEN1
48 familial hypocalciuric hypercalcemia 31.8 RET MEN1 CDKN2C CDKN1B CDC73 CASR
49 prolactin producing pituitary tumor 31.8 PRL MEN1
50 mineral metabolism disease 31.8 MEN1 CDC73 CASR
51 gastric gastrinoma 31.8 SST SCT MEN1 GAST CHGA
52 cardiovascular organ benign neoplasm 31.8 SDHD RET MEN1 CHGA
53 pancreatic cholera 31.8 SST SCT MEN1 GAST CHGA
54 endocrine pancreas disease 31.8 SST SCT MEN1 GAST CHGA
55 hyperparathyroidism 31.8 SCT RET PRKAR1A MEN1 GAST CHGA
56 duodenal somatostatinoma 31.8 SST SCT MEN1 GAST CHGA
57 esophageal neuroendocrine tumor 31.8 SST SCT MEN1 GAST CHGA
58 duodenum cancer 31.8 SST SCT MEN1 GAST CHGA
59 duodenum disease 31.8 SST SCT MEN1 GAST CHGA
60 pancreatic cystadenoma 31.8 SST SCT MEN1 GAST CHGA
61 adrenal cortex disease 31.8 PRL PRKAR1A MEN1
62 li-fraumeni syndrome 31.7 PRKAR1A MEN1 CDKN2B CDKN1A
63 hypertension, essential 31.7 SST RET PRL MEN1 GNAS CHGA
64 functioning pituitary adenoma 31.7 SST PRL PRKAR1A MEN1 GNAS CDKN1B
65 hyperpituitarism 31.7 SST PRL PRKAR1A MEN1 GNAS
66 cowden syndrome 31.7 SDHD RET PRKAR1A MEN1
67 multiple endocrine neoplasia 31.7 SST SDHD SCT RET PYGM PRL
68 adrenal gland disease 31.7 SST PRL PRKAR1A MEN1 GNAS CHGA
69 lissencephaly, x-linked, 2 31.7 SST PRL PRKAR1A MEN1 GNAS CDKN1B
70 carcinoid tumors, intestinal 31.6 SST MEN1 GAST CHGA
71 endocrine organ benign neoplasm 31.6 SST SDHD RET PRL PRKAR1A MEN1
72 gastrinoma 31.5 SST SCT MEN1 GAST CHGA CASR
73 carcinoid syndrome 31.5 SST SDHD CHGA
74 diabetes mellitus 31.5 SST SCT PRL MEN1 GAST CHGA
75 primary hyperparathyroidism 31.4 SCT RET PRL PRKAR1A MEN1 GAST
76 islet cell tumor 31.4 SST SCT RET MEN1 GAST CHGA
77 acromegaly 31.4 SST PRL MEN1 GNAS
78 pituitary adenoma 31.4 SST RET PRL PRKAR1A MEN1 GNAS
79 hyperprolactinemia 31.4 SST PRL GNAS
80 pituitary tumors 31.3 SST PRL MEN1 GNAS
81 hyperinsulinemic hypoglycemia 31.3 SST SCT MEN1 GAST CHGA
82 prolactinoma 31.2 SST PRL PRKAR1A MEN1 GNAS CHGA
83 hyperinsulinemic hypoglycemia, familial, 2 31.2 SST SCT GAST CHGA
84 hypoglycemia 31.2 SST SCT PRL GAST CHGA
85 neuroendocrine tumor 31.2 SST SDHD SCT RET MEN1 GAST
86 conn's syndrome 31.2 SST RET PRL PRKAR1A MEN1 GNAS
87 adenoma 31.2 SST RET PRL PRKAR1A MEN1 GNAS
88 adrenal adenoma 31.2 PRKAR1A MEN1 GNAS
89 pituitary-dependent cushing's disease 31.1 SST PRL
90 glucagonoma 31.0 SST SCT GAST CHGA
91 peptic ulcer disease 31.0 SST SCT MEN1 GAST
92 vipoma 31.0 SST SCT MEN1 GAST CHGA
93 inherited cancer-predisposing syndrome 30.9 SDHD RET MEN1 CDKN1B CDC73
94 bap1 tumor predisposition syndrome 30.9 SDHD RET MEN1 CDKN1B CDC73
95 endocrine gland cancer 30.9 SST RET GNAS GAST CHGA
96 adrenal carcinoma 30.9 SST SDHD RET PRKAR1A MEN1 CHGA
97 pituitary gland disease 30.9 SST PRL PRKAR1A MEN1 GNAS CDKN1B
98 pituitary adenoma 1, multiple types 30.8 SST PRL MEN1
99 pernicious anemia 30.8 SST GAST CHGA
100 ganglioneuroma 30.8 SST RET CHGA
101 neuroendocrine carcinoma 30.8 SST MEN1 GAST CHGA
102 gastritis 30.8 SST SCT GAST CHGA
103 malignant pheochromocytoma 30.8 SST SDHD RET CHGA
104 parathyroid carcinoma 30.8 RET MEN1 CDC73 CASR
105 pancreatic gastrinoma 30.8 SST SCT MEN1 GAST CHGA
106 adrenal cortical adenoma 30.8 SDHD PRKAR1A MEN1 CHGA
107 osteitis fibrosa 30.7 GNAS CDC73 CASR
108 papillary carcinoma 30.7 RET GNAS CHGA CDKN1B
109 nonsyndromic paraganglioma 30.7 RET CHGA
110 duodenal ulcer 30.7 SST SCT GAST
111 primary pigmented nodular adrenocortical disease 30.7 PRL PRKAR1A MEN1 GNAS
112 parathyroid adenoma 30.7 RET PRL PRKAR1A MEN1 GNAS GAST
113 goiter 30.7 SST RET PRL GNAS
114 hypoparathyroidism 30.7 RET PRKAR1A GNAS CASR
115 thyroid carcinoma, familial medullary 30.7 SST RET PRKAR1A MEN1 GAST CHGA
116 growth hormone secreting pituitary adenoma 30.7 SST PRL PRKAR1A MEN1 GNAS
117 pituitary cancer 30.7 SST PRL PRKAR1A MEN1 GNAS CDKN1B
118 meningioma, familial 30.6 SST RET PRL PRKAR1A MEN1 CDKN2C
119 pheochromocytoma 30.5 SST SDHD RET PRL MEN1 CHGA
120 carney complex variant 30.5 SST SDHD RET PRL PRKAR1A MEN1
121 small cell cancer of the lung 30.5 SST GAST CHGA
122 ectopic cushing syndrome 30.5 SST PRL CHGA
123 gangliocytoma 30.5 SST PRL CHGA
124 hypothyroidism 30.4 SST RET PRL GNAS
125 dumping syndrome 30.2 SST SCT GAST
126 acth-independent cushing syndrome 30.2 PRKAR1A GNAS
127 gastroparesis 30.2 SST SCT GAST
128 hyperparathyroidism, neonatal severe 30.2 PRKAR1A CASR
129 constipation 30.2 SST RET GAST CHGA
130 hyperthyroidism 30.0 SST PRL GNAS
131 thymic neuroendocrine tumor 11.3
132 grfoma 11.3
133 bronchial neuroendocrine tumor 11.3
134 lipomatosis 11.0
135 hemangioma 10.9
136 fanconi anemia, complementation group a 10.9
137 carney complex, type 1 10.9
138 small intestine cancer 10.9
139 cellular ependymoma 10.8
140 alpha-thalassemia 10.8
141 lynch syndrome 10.8
142 hereditary breast ovarian cancer syndrome 10.8
143 beckwith-wiedemann syndrome 10.8
144 mahvash disease 10.8
145 cecum adenoma 10.8
146 cell type benign neoplasm 10.8
147 ureter leiomyoma 10.8
148 cecal benign neoplasm 10.8
149 tanycytic ependymoma 10.8
150 parathyroid transitional clear cell adenoma 10.8
151 pancreatic cancer 10.7
152 hypercalcemia, infantile, 1 10.6
153 colon neuroendocrine neoplasm 10.5 SST GAST CHGA
154 benign ileal neoplasm 10.5 SST GAST CHGA
155 duodenal benign neoplasm 10.5 SST CHGA
156 ampulla of vater benign neoplasm 10.5 SST CHGA
157 endometrial small cell carcinoma 10.5 SST GAST CHGA
158 meckel diverticulum 10.5 SST GAST CHGA
159 water-clear cell adenoma 10.5 CDKN2C CDC73
160 extra-adrenal pheochromocytoma 10.5 SDHD RET CHGA
161 chiasmal syndrome 10.5 SST PRL
162 common bile duct neoplasm 10.5 SST SCT GNAS
163 sporadic pheochromocytoma/secreting paraganglioma 10.5 SDHD RET
164 rectum neuroendocrine neoplasm 10.5 SST GAST
165 basophil adenoma 10.5 PRKAR1A GNAS
166 duodenogastric reflux 10.4 SST SCT GAST
167 persistent generalized lymphadenopathy 10.4 SDHD RET CHGA
168 carotid body cancer 10.4 SDHD CHGA
169 pyloric stenosis 10.4 SST RET GAST
170 adrenal medulla cancer 10.4 SST SDHD RET CHGA
171 autonomic nervous system benign neoplasm 10.4 SST SDHD RET CHGA
172 peripheral nervous system benign neoplasm 10.4 SST SDHD RET CHGA
173 thyroid gland disease 10.4 SST RET PRL GNAS
174 appendiceal neoplasm 10.4 GNAS CHGA
175 acute hemorrhagic pancreatitis 10.4 SST SCT
176 laryngeal neuroendocrine tumor 10.4 RET CHGA
177 acidophil adenoma 10.4 SST PRL
178 tricuspid valve stenosis 10.4 SST CHGA
179 melanoma, cutaneous malignant 1 10.4 CDKN2C CDKN2B CDKN1B CDKN1A
180 lymphoblastic lymphoma 10.4 CDKN2B CDKN1B CDKN1A
181 tsh producing pituitary tumor 10.4 SST PRL
182 hypocalcemia, autosomal dominant 1 10.4 PRKAR1A GNAS CASR
183 fibrous dysplasia 10.4 SST PRL GNAS CDC73
184 gastric hemangioma 10.4 SST CHGA
185 thyroid gland hurthle cell carcinoma 10.4 CHGA CDC73
186 pseudohypoparathyroidism 10.4 PRL PRKAR1A GNAS
187 appendix adenocarcinoma 10.4 GNAS CHGA
188 biliary dyskinesia 10.4 SST SCT
189 hyperinsulinism 10.4
190 thyroid dyshormonogenesis 2a 10.4 SST RET
191 melanotic neurilemmoma 10.4 PRL PRKAR1A
192 breast adenoma 10.3 PRL PRKAR1A
193 thyroid tumor 10.3 RET PRKAR1A
194 ewing sarcoma 10.3
195 lipomatosis, multiple 10.3
196 nephrolithiasis, calcium oxalate 10.3
197 galactorrhea 10.3
198 amenorrhea 10.3
199 thyroid carcinoma 10.3
200 diarrhea 4, malabsorptive, congenital 10.3 SCT CHGA
201 gallbladder disease 1 10.3
202 impotence 10.3
203 acute pancreatitis 10.3
204 kidney disease 10.3
205 bronchial adenomas/carcinoids childhood 10.3
206 functioning neuroendocrine tumor of pancreas 10.3
207 non-functioning neuroendocrine tumor of pancreas 10.3
208 thymic neuroendocrine carcinoma 10.3
209 rhabdomyosarcoma 10.3 RET CHGA CDKN2B CDKN1B CDKN1A
210 vallecula cancer 10.3 CDKN2B CDKN1B
211 skin melanoma 10.2 GNAS CDKN2B CDKN1A
212 diarrhea 10.2
213 chromophobe adenoma 10.2
214 polyendocrinopathy 10.2
215 cerebral angioma 10.2 SDHD RET
216 basal cell nevus syndrome 10.2
217 polycystic liver disease 1 with or without kidney cysts 10.2
218 familial adenomatous polyposis 1 10.2
219 bone mineral density quantitative trait locus 3 10.2
220 nemaline myopathy 1 10.2
221 premature ovarian failure 7 10.2
222 familial adenomatous polyposis 10.2
223 pre-eclampsia 10.2
224 hydrocephalus 10.2
225 hyperandrogenism 10.2
226 esophagitis 10.2
227 nephrocalcinosis 10.2
228 polyneuropathy 10.2
229 glossitis 10.2
230 myoma 10.2
231 acute kidney failure 10.2
232 angiomyolipoma 10.2
233 mesenchymal cell neoplasm 10.2
234 pancreatitis 10.2
235 lymphatic system disease 10.2
236 kidney angiomyolipoma 10.2
237 duodenitis 10.2
238 49, xxxxy syndrome 10.2
239 49,xxxxx syndrome 10.2
240 neuroendocrine carcinoma of pancreas 10.2
241 49,xyyyy syndrome 10.2
242 hypervitaminosis a 10.2 CDKN1B CDKN1A
243 retinoblastoma 10.1
244 rare tumor 10.1
245 adrenocortical carcinoma, hereditary 10.1
246 neuroendocrine neoplasm of pancreas 10.1
247 amenorrhea-galactorrhea syndrome 10.1
248 renal cell carcinoma, nonpapillary 10.1
249 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.1
250 thyroid cancer, nonmedullary, 1 10.1
251 tuberous sclerosis 1 10.1
252 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 10.1
253 3-methylglutaconic aciduria, type iii 10.1
254 insulin-like growth factor i 10.1
255 werner syndrome 10.1
256 orthostatic intolerance 10.1
257 major depressive disorder 10.1
258 tuberous sclerosis 2 10.1
259 hypophosphatemia 10.1
260 urolithiasis 10.1
261 urinary tract infection 10.1
262 gastric ulcer 10.1
263 hypertensive heart disease 10.1
264 cryptococcosis 10.1
265 nodular goiter 10.1
266 tuberous sclerosis 10.1
267 calcinosis 10.1
268 thymoma 10.1
269 thymus cancer 10.1
270 empty sella syndrome 10.1
271 pancreatic adenocarcinoma 10.1
272 hypokalemia 10.1
273 uremia 10.1
274 nephrolithiasis 10.1
275 alopecia 10.1
276 47 xxx syndrome 10.1
277 galactorrhoea-hyperprolactinaemia 10.1
278 vibrio vulnificus infection 10.1
279 argyria 10.1
280 neurofibromatosis, type ii 10.1
281 autoimmune disease 10.1
282 gastroesophageal reflux 10.1
283 lymphoma, mucosa-associated lymphoid type 10.1
284 hashimoto thyroiditis 10.1
285 lipomatosis, multiple symmetric 10.1
286 osteoporosis 10.1
287 pancreatitis, hereditary 10.1
288 prader-willi syndrome 10.1
289 polycystic ovary syndrome 1 10.1
290 tobacco addiction 10.1
291 autism 10.1
292 premature centromere division 10.1
293 chondrosarcoma 10.1
294 type 1 diabetes mellitus 10.1
295 myasthenia gravis 10.1
296 ocular motor apraxia 10.1
297 testicular germ cell tumor 10.1
298 orofaciodigital syndrome viii 10.1
299 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 10.1
300 oncocytoma 10.1
301 adenomyosis 10.1
302 stroke, ischemic 10.1
303 inflammatory bowel disease 7 10.1
304 hyperparathyroidism 3 10.1
305 bone mineral density quantitative trait locus 8 10.1
306 lung cancer susceptibility 3 10.1
307 bone mineral density quantitative trait locus 15 10.1
308 gastric cancer 10.1
309 barrett esophagus 10.1
310 peripartum cardiomyopathy 10.1
311 gastric adenocarcinoma and proximal polyposis of the stomach 10.1
312 aspiration pneumonia 10.1
313 inflammatory bowel disease 10.1
314 metabolic acidosis 10.1
315 autism spectrum disorder 10.1
316 angular cheilitis 10.1
317 b-lymphoblastic leukemia/lymphoma 10.1
318 diffuse gastric cancer 10.1
319 hypogonadotropic hypogonadism 10.1
320 spermatogenic failure 10.1
321 cholelithiasis 10.1
322 pyelonephritis 10.1
323 cauda equina syndrome 10.1
324 polycystic ovary syndrome 10.1
325 prediabetes syndrome 10.1
326 visual epilepsy 10.1
327 nephrogenic diabetes insipidus 10.1
328 enterocele 10.1
329 severe pre-eclampsia 10.1
330 glanders 10.1
331 peptic esophagitis 10.1
332 obstructive hydrocephalus 10.1
333 cholera 10.1
334 hypoglycemic coma 10.1
335 cheilitis 10.1
336 vascular disease 10.1
337 epilepsy 10.1
338 thrombophilia 10.1
339 gastric antral vascular ectasia 10.1
340 testicular disease 10.1
341 testicular cancer 10.1
342 teratoma 10.1
343 bone inflammation disease 10.1
344 skin carcinoma 10.1
345 signet ring cell adenocarcinoma 10.1
346 central nervous system cancer 10.1
347 intermittent claudication 10.1
348 skin disease 10.1
349 seminoma 10.1
350 collecting duct carcinoma 10.1
351 esophagus adenocarcinoma 10.1
352 infertility 10.1
353 mediastinal cancer 10.1
354 peripheral nervous system disease 10.1
355 malignant peripheral nerve sheath tumor 10.1
356 esophageal disease 10.1
357 follicular adenoma 10.1
358 renal oncocytoma 10.1
359 diffuse idiopathic skeletal hyperostosis 10.1
360 thyroiditis 10.1
361 pancreatic intraductal papillary-colloid carcinoma 10.1
362 situs inversus 10.1
363 whipple disease 10.1
364 neuropathy 10.1
365 intracranial hypertension 10.1
366 neurofibroma 10.1
367 aip familial isolated pituitary adenomas 10.1
368 factor v leiden thrombophilia 10.1
369 pik3ca-related overgrowth spectrum 10.1
370 aortopulmonary window 10.1
371 children's interstitial lung disease 10.1
372 dextrocardia with situs inversus 10.1
373 erythrokeratoderma ''en cocardes'' 10.1
374 glioma 10.1
375 human t-cell leukemia virus type 1 10.1
376 pancreatic adenoma 10.1
377 secondary adrenal insufficiency 10.1
378 cerebral aneurysms 10.1
379 glial tumor 10.1
380 congenital aortopulmonary window 10.1
381 somatomammotropinoma 10.1
382 pik3ca-related overgrowth syndrome 10.1
383 adenoma of pancreas 10.1
384 overgrowth syndrome 10.1
385 leukemia 10.1
386 pituitary adenoma 4, acth-secreting 10.0
387 factor vii deficiency 10.0
388 gastrointestinal defects and immunodeficiency syndrome 1 10.0
389 ceroid lipofuscinosis, neuronal, 5 10.0
390 ataxia with vitamin e deficiency 10.0
391 alpha-thalassemia/mental retardation syndrome, x-linked 10.0
392 leiomyoma 10.0
393 hyperglycemia 10.0
394 contractural arachnodactyly, congenital 10.0
395 myotonic dystrophy 1 10.0
396 paragangliomas 1 10.0
397 pectus excavatum 10.0
398 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
399 pulmonary arteriovenous fistulas 10.0
400 alpha-1-antitrypsin deficiency 10.0
401 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.0
402 chronic pyelonephritis 10.0
403 bronchus cancer 10.0
404 neuroma 10.0
405 endometrial adenocarcinoma 10.0
406 lactic acidosis 10.0
407 bladder adenocarcinoma 10.0
408 myopathy 10.0
409 adenomatoid tumor 10.0
410 diverticulitis 10.0
411 eisenmenger syndrome 10.0
412 metabolic myopathy 10.0
413 brittle bone disorder 10.0
414 graves' disease 10.0
415 juvenile xanthogranuloma 10.0
416 klebsiella infection 10.0
417 gynecomastia 10.0
418 cutis laxa 10.0
419 chromosome xq26.3 duplication syndrome 10.0
420 rickets 10.0
421 melanoma 10.0
422 adenocarcinoma 10.0
423 chronic kidney disease 10.0
424 hypopituitarism 10.0
425 aldosterone-producing adenoma 10.0
426 burkitt lymphoma 9.9
427 cherubism 9.9
428 down syndrome 9.9
429 lung cancer 9.9
430 fanconi anemia, complementation group d2 9.9
431 ichthyosis, congenital, autosomal recessive 1 9.9
432 tumor suppressor gene on chromosome 11 9.9
433 multinodular goiter 9.9
434 lymphoma 9.9
435 ptosis 9.9
436 bone resorption disease 9.9
437 cystadenoma 9.9
438 pulmonary fibrosis 9.9
439 cranial nerve palsy 9.9
440 cavernous hemangioma 9.9
441 ovarian serous cystadenocarcinoma 9.9
442 b-cell lymphoma 9.9
443 end stage renal disease 9.9
444 lung disease 9.9
445 cdc73-related disorders 9.9
446 alcohol dependence 9.9
447 alcohol use disorder 9.9
448 cardiac arrest 9.8
449 thrombotic thrombocytopenic purpura 9.8
450 disseminated intravascular coagulation 9.8
451 arteriovenous malformation 9.8
452 hereditary hemorrhagic telangiectasia 9.8
453 telangiectasis 9.8
454 gastrin secretion abnormality 9.8
455 papillary adenocarcinoma 9.8
456 purpura 9.8
457 liver cirrhosis 9.8
458 hemolytic anemia 9.8
459 prostatic hyperplasia, benign 9.8
460 breast cancer 9.7
461 hepatocellular carcinoma 9.7
462 lynch syndrome i 9.7
463 diabetes insipidus, neurohypophyseal 9.7
464 exostoses, multiple, type i 9.7
465 glioma susceptibility 1 9.7
466 leiomyoma, uterine 9.7
467 lentigines 9.7
468 oculodentodigital dysplasia 9.7
469 ovarian cancer 9.7
470 porokeratosis 2, palmar, plantar, and disseminated type 9.7
471 prostate cancer 9.7
472 neural tube defects 9.7
473 thrombophilia due to thrombin defect 9.7
474 hypothyroidism, congenital, nongoitrous, 2 9.7
475 hyperinsulinemic hypoglycemia, familial, 1 9.7
476 pituitary hormone deficiency, combined, 2 9.7
477 pyruvate carboxylase deficiency 9.7
478 graves disease 1 9.7
479 hypophosphatemic rickets, x-linked recessive 9.7
480 leukemia, acute myeloid 9.7
481 neural tube defects, folate-sensitive 9.7
482 hyperinsulinemic hypoglycemia, familial, 3 9.7
483 ventricular fibrillation, paroxysmal familial, 1 9.7
484 renal cell carcinoma, papillary, 1 9.7
485 spastic paraplegia, ataxia, and mental retardation 9.7
486 ovarian cancer 1 9.7
487 hypothyroidism, congenital, nongoitrous, 3 9.7
488 hyperinsulinemic hypoglycemia, familial, 5 9.7
489 hyperinsulinemic hypoglycemia, familial, 4 9.7
490 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 9.7
491 leukemia, acute lymphoblastic 9.7
492 tumor predisposition syndrome 1 9.7
493 bone mineral density quantitative trait locus 16 9.7
494 alacrima, achalasia, and mental retardation syndrome 9.7
495 acth-independent macronodular adrenal hyperplasia 2 9.7
496 periventricular nodular heterotopia 9.7
497 renal fibrosis 9.7
498 fibroma 9.7
499 pancreatic agenesis 9.7
500 ductal carcinoma in situ 9.7
501 bone disease 9.7
502 thyroid gland anaplastic carcinoma 9.7
503 myxofibrosarcoma 9.7
504 central diabetes insipidus 9.7
505 acute myelomonocytic leukemia 9.7
506 thalassemia 9.7
507 osteomalacia 9.7
508 glucose intolerance 9.7
509 portal hypertension 9.7
510 alport syndrome 9.7
511 sarcoma 9.7
512 pituitary apoplexy 9.7
513 megacolon 9.7
514 gestational diabetes 9.7
515 pericardial effusion 9.7
516 acute leukemia 9.7
517 acoustic neuroma 9.7
518 brain cancer 9.7
519 exocrine pancreatic insufficiency 9.7
520 cholestasis 9.7
521 obstructive jaundice 9.7
522 hypogonadism 9.7
523 leiomyosarcoma 9.7
524 rectum adenocarcinoma 9.7
525 exostosis 9.7
526 focal epilepsy 9.7
527 splenic infarction 9.7
528 kidney cancer 9.7
529 chondroblastoma 9.7
530 cockayne syndrome 9.7
531 neurilemmoma 9.7
532 thymic carcinoma 9.7
533 bipolar disorder 9.7
534 fibrosarcoma 9.7
535 lung benign neoplasm 9.7
536 gastric adenocarcinoma 9.7
537 high grade ependymoma 9.7
538 ureteral obstruction 9.7
539 spinal cord ependymoma 9.7
540 congestive heart failure 9.7
541 inherited metabolic disorder 9.7
542 skin tag 9.7
543 chief cell adenoma 9.7
544 myeloid leukemia 9.7
545 in situ carcinoma 9.7
546 rosacea 9.7
547 diabetes insipidus 9.7
548 bacterial meningitis 9.7
549 meningitis 9.7
550 hereditary multiple osteochondromas 9.7
551 acute monoblastic leukemia 9.7
552 acute myeloblastic leukemia with maturation 9.7
553 acute myeloid leukemia with recurrent genetic anomaly 9.7
554 cerebrospinal fluid leak 9.7
555 chromosomal triplication 9.7
556 gastro-enteropancreatic neuroendocrine tumor 9.7
557 granulosa cell tumor of the ovary 9.7
558 haemophilus influenzae 9.7
559 metastatic insulinoma 9.7
560 osteochondroma 9.7
561 precocious puberty 9.7
562 back pain 9.7
563 posttransplant acute limbic encephalitis 9.7
564 acute monoblastic/monocytic leukemia 9.7
565 non-functioning pituitary adenoma 9.7
566 functioning gonadotropic adenoma 9.7
567 pigmentation anomaly of the skin 9.7
568 ppoma 9.7
569 pheochromocytoma-paraganglioma 9.7
570 gastroenteropancreatic neuroendocrine neoplasm 9.7
571 duodenal neuroendocrine tumor 9.7
572 apnea, obstructive sleep 9.7
573 immune deficiency disease 9.7
574 neurofibromatosis-noonan syndrome 9.7
575 anxiety 9.7
576 myocardial infarction 9.7
577 muscle hypertrophy 9.7
578 exanthem 9.7
579 sleep apnea 9.7
580 sexual health disorder 9.7
581 rapidly involuting congenital hemangioma 9.7
582 prostatic hypertrophy 9.7
583 varicocele 9.7
584 arteriosclerosis 9.7
585 benign mesothelioma 9.7
586 vaccinia 9.7
587 poliomyelitis 9.7
588 neurotic disorder 9.7
589 acquired immunodeficiency syndrome 9.7
590 gastrointestinal system disease 9.7
591 neurofibromatosis 9.7
592 acute myocardial infarction 9.7
593 spinal cord injury 9.7
594 bladder diverticulum 9.7
595 lipoid congenital adrenal hyperplasia 9.7
596 helicobacter pylori infection 9.7
597 prostate cancer, hereditary, 8 9.7
598 prostate cancer, hereditary, 6 9.7
599 peripheral vascular disease 9.7
600 alpha thalassemia-x-linked intellectual disability syndrome 9.7
601 renal hypertension 9.7
602 ehlers-danlos syndrome 9.7
603 endodermal sinus tumor 9.7
604 pancreatic ductal adenocarcinoma 9.7
605 rhinitis 9.7
606 prostate disease 9.7
607 epithelial-myoepithelial carcinoma 9.7
608 clear cell adenoma 9.7
609 mature teratoma 9.7
610 chronic rhinitis 9.7
611 peliosis hepatis 9.7
612 pulmonary embolism 9.7
613 pure autonomic failure 9.7
614 syncope 9.7
615 cardiogenic shock 9.7
616 acute adrenal insufficiency 9.7

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia, Type I:



Diseases related to Multiple Endocrine Neoplasia, Type I

Symptoms & Phenotypes for Multiple Endocrine Neoplasia, Type I

Human phenotypes related to Multiple Endocrine Neoplasia, Type I:

58 30 (showing 88, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypercalcemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003072
2 primary hyperparathyroidism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008200
3 parathyroid hyperplasia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008208
4 angiofibromas 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0010615
5 impairment of activities of daily living 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0031058
6 gastroesophageal reflux 58 30 Frequent (33%) Frequent (79-30%)
HP:0002020
7 reduced bone mineral density 58 30 Frequent (33%) Frequent (79-30%)
HP:0004349
8 multiple lipomas 58 30 Frequent (33%) Frequent (79-30%)
HP:0001012
9 abdominal pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0002027
10 hypercalciuria 58 30 Frequent (33%) Frequent (79-30%)
HP:0002150
11 peptic ulcer 58 30 Frequent (33%) Frequent (79-30%)
HP:0004398
12 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
13 impotence 58 30 Frequent (33%) Frequent (79-30%)
HP:0000802
14 pituitary prolactin cell adenoma 58 30 Frequent (33%) Frequent (79-30%)
HP:0006767
15 galactorrhea 58 30 Frequent (33%) Frequent (79-30%)
HP:0100829
16 hypergastrinemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0500167
17 zollinger-ellison syndrome 58 30 Frequent (33%) Frequent (79-30%)
HP:0002044
18 decreased male libido 58 30 Frequent (33%) Frequent (79-30%)
HP:0040306
19 adrenocortical abnormality 58 30 Frequent (33%) Frequent (79-30%)
HP:0000849
20 large cafe-au-lait macules with irregular margins 58 30 Frequent (33%) Frequent (79-30%)
HP:0005605
21 constipation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002019
22 hypertension 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000822
23 dehydration 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001944
24 vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002013
25 anorexia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002039
26 nephrolithiasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000787
27 hematemesis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002248
28 headache 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002315
29 meningioma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002858
30 goiter 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000853
31 lethargy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001254
32 adrenocortical carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006744
33 osteolysis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002797
34 pituitary growth hormone cell adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011760
35 thyroid carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002890
36 increased susceptibility to fractures 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002659
37 confusion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001289
38 short attention span 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000736
39 gingival fibromatosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000169
40 amenorrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000141
41 duodenal ulcer 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002588
42 nausea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002018
43 melena 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002249
44 shortened qt interval 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012232
45 proportionate tall stature 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011407
46 intestinal carcinoid 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006723
47 insulinoma 58 30 Very rare (1%) Occasional (29-5%)
HP:0012197
48 confetti-like hypopigmented macules 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0007449
49 primary hypercortisolism 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001579
50 cranial nerve compression 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001293
51 abnormal circulating aldosterone 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0040085
52 decreased vigilance 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0032044
53 elevated circulating growth hormone concentration 30 Occasional (7.5%) HP:0000845
54 depression 30 Occasional (7.5%) HP:0000716
55 pheochromocytoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002666
56 coma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001259
57 thymoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100522
58 pulmonary carcinoid tumor 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030445
59 pituitary corticotropic cell adenoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0008291
60 parathyroid carcinoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0006780
61 elevated calcitonin 58 30 Very rare (1%) Very rare (<4-1%)
HP:0003528
62 pituitary gonadotropic cell adenoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011759
63 pituitary thyrotropic cell adenoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011762
64 pituitary adenoma 58 30 Very rare (1%) Frequent (79-30%)
HP:0002893
65 pituitary null cell adenoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011761
66 carcinoid tumor 58 30 Very rare (1%) Occasional (29-5%)
HP:0100570
67 glucagonoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030404
68 increased serum serotonin 58 30 Very rare (1%) Very rare (<4-1%)
HP:0003144
69 ependymoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002888
70 adrenocortical adenoma 30 Very rare (1%) HP:0008256
71 prolactinoma 30 Very rare (1%) HP:0040278
72 atypical absence status epilepticus 30 Very rare (1%) HP:0011151
73 diarrhea 58 30 Frequent (79-30%)
HP:0002014
74 increased circulating cortisol level 58 30 Occasional (29-5%)
HP:0003118
75 depressivity 58 Occasional (29-5%)
76 hypoglycemia 30 HP:0001943
77 adenoma sebaceum 30 HP:0009720
78 growth hormone excess 58 Occasional (29-5%)
79 neoplasm of the pancreas 58 Frequent (79-30%)
80 cafe-au-lait spot 30 HP:0000957
81 subcutaneous lipoma 30 HP:0001031
82 esophagitis 30 HP:0100633
83 parathyroid adenoma 30 HP:0002897
84 pancreatic endocrine tumor 58 Occasional (29-5%)
85 thyroid adenoma 30 HP:0000854
86 increased circulating prolactin concentration 30 HP:0000870
87 pancreatic islet cell adenoma 30 HP:0008261
88 obtundation status 58 Very rare (<4-1%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Laboratory Abnormalities:
hypoglycemia
hypercalcemia
elevated acth
abnormal secretin test
elevated gastrin concentration
more
Endocrine Features:
parathyroid adenoma
pituitary adenoma
glucagonoma
insulinoma
pancreatic islet cell adenoma
more
Neoplasia:
carcinoid tumors

Abdomen Gastrointestinal:
diarrhea
esophagitis
zollinger-ellison syndrome
intractable peptic ulcer

Skin Nails Hair Skin:
confetti-like hypopigmented macules
subcutaneous lipomas
facial angiofibromas
collagenomas
cafe-au-lait macules
more

Clinical features from OMIM®:

131100 (Updated 24-Oct-2022)

UMLS symptoms related to Multiple Endocrine Neoplasia, Type I:


diarrhea

GenomeRNAi Phenotypes related to Multiple Endocrine Neoplasia, Type I according to GeneCards Suite gene sharing:

25 (showing 10, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
2 no effect GR00402-S-2 10.2 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
3 Decreased viability GR00221-A-1 9.91 CDKN1B CDKN2C PRKAR1A RET SDHD
4 Decreased viability GR00221-A-2 9.91 PRKAR1A RET SDHD
5 Decreased viability GR00221-A-3 9.91 PRKAR1A
6 Decreased viability GR00221-A-4 9.91 PRKAR1A RET SDHD
7 Decreased viability GR00249-S 9.91 CDKN2C SDHD
8 Decreased viability GR00301-A 9.91 CDKN2C RET
9 Decreased viability GR00381-A-1 9.91 SDHD
10 Decreased viability GR00402-S-2 9.91 RET

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia, Type I:

45 (showing 21, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.54 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
2 neoplasm MP:0002006 10.41 CDC73 CDKN1A CDKN1B CDKN2B CDKN2C GAST
3 endocrine/exocrine gland MP:0005379 10.41 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
4 nervous system MP:0003631 10.36 CDC73 CDKN1A CDKN1B CDKN2C CHGA GNAS
5 growth/size/body region MP:0005378 10.34 CASR CDC73 CDKN1A CDKN1B CDKN2C CHGA
6 renal/urinary system MP:0005367 10.32 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
7 muscle MP:0005369 10.31 CASR CDC73 CDKN1A CDKN1B CHGA GNAS
8 behavior/neurological MP:0005386 10.31 CASR CDC73 CDKN1A CDKN1B CDKN2C GNAS
9 immune system MP:0005387 10.24 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
10 cellular MP:0005384 10.23 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
11 cardiovascular system MP:0005385 10.17 CDC73 CDKN1A CDKN1B CDKN2C CHGA GNAS
12 liver/biliary system MP:0005370 10.16 CDC73 CDKN1A CDKN1B GNAS JUND MEN1
13 embryo MP:0005380 10.15 CDC73 CDKN1A CDKN1B JUND MEN1 PLCB3
14 no phenotypic analysis MP:0003012 10.14 CDKN1A CDKN1B CDKN2B CHGA GNAS RET
15 digestive/alimentary MP:0005381 10.13 CASR CDC73 CDKN1A CDKN1B GAST MEN1
16 adipose tissue MP:0005375 10.09 CDC73 CDKN1A CDKN1B GNAS JUND PRKAR1A
17 reproductive system MP:0005389 10.03 CDC73 CDKN1A CDKN1B CDKN2B CDKN2C CHGA
18 respiratory system MP:0005388 9.97 CDC73 CDKN1A CDKN1B CDKN2C GNAS JUND
19 hematopoietic system MP:0005397 9.93 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
20 mortality/aging MP:0010768 9.89 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C
21 integument MP:0010771 9.32 CASR CDC73 CDKN1A CDKN1B CDKN2B CDKN2C

Drugs & Therapeutics for Multiple Endocrine Neoplasia, Type I

Drugs for Multiple Endocrine Neoplasia, Type I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 48, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3 Gastrointestinal Agents Phase 4
4 Anti-Ulcer Agents Phase 4
5 Proton Pump Inhibitors Phase 4
6 Antacids Phase 4
7
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605 16129706
8 Hormones Phase 3
9 Hormone Antagonists Phase 3
10
Aflibercept Approved Phase 2 862111-32-8 124490314
11
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
12
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
13
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
14
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
15
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
17
Pertuzumab Approved Phase 2 380610-27-5
18
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
19 Mitogens Phase 2
20 Angiogenesis Inhibitors Phase 2
21 Endothelial Growth Factors Phase 2
22 Antineoplastic Agents, Hormonal Phase 2
23 Dihydroxyphenylalanine Phase 2
24 Immunosuppressive Agents Phase 2
25 Immunologic Factors Phase 2
26 Protein Kinase Inhibitors Phase 2
27 Antineoplastic Agents, Immunological Phase 2
28 gamma-Globulins Phase 1
29 Antibodies Phase 1
30 Rho(D) Immune Globulin Phase 1
31 Immunoglobulins, Intravenous Phase 1
32 Immunoglobulins Phase 1
33
Morphine Approved, Investigational 57-27-2 5288826
34
Vancomycin Approved 1404-90-6 14969
35
Histamine Approved, Investigational 51-45-6 774
36
Ethanol Approved 64-17-5 702
37
Polidocanol Approved 9002-92-0 78933
38
Salmon calcitonin Approved, Investigational 47931-85-1 155817456
39
Formaldehyde Approved, Vet_approved 50-00-0 712
40
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Early Phase 1 63-91-2, 673-06-3 6140 71567
41
Calcitonin gene-related peptide Investigational 83652-28-2 91976570
42
Histamine phosphate 51-74-1 134614
43 Calcium, Dietary
44
Calcitonin
45 Katacalcin 16172926
46 Radiopharmaceuticals Early Phase 1
47
Edotreotide Early Phase 1 23724894
48
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(showing 36, show less)
# Name Status NCT ID Phase Drugs
1 Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
2 Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
3 Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT02101918 Phase 2
4 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
5 Studies of Hyperparathyroidism and Related Disorders Completed NCT00001277 Phase 2 68Ga-Dotatate;18F-DOPA
6 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Completed NCT00514046 Phase 1, Phase 2 Vandetanib
7 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
8 A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Completed NCT00358956 Phase 2 ZD6474 (vandetanib)
9 A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors Recruiting NCT03950609 Phase 2 Everolimus;Lenvatinib
10 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib Tosylate
11 A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Terminated NCT00947167 Phase 2 pertuzumab;erlotinib
12 The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial Completed NCT00001550 Phase 1 IVIg
13 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
14 A Pilot Study to Investigate Germ-Line MEN1 and SDHD Gene Mutation in Familial Cases of Carcinoid Cancer Unknown status NCT00672269
15 Type 1 Multiple Endocrine Neoplasia : a Cohort Study of the Endocrine Tumor Study Group (GTE) Unknown status NCT03262129
16 Revisiting the Evidence for Routine Transcervical Thymectomy for the Prevention of Thymic Carcinoid Tumours in MEN-1 Patients a Case Series Completed NCT05061784
17 A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
18 Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Completed NCT01424878
19 Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes Completed NCT00501449
20 Genetic Polymorphisms Associated With Histamine Disposition in Children With Vancomycin Associated Red Man Syndrome (RMS) Completed NCT00824122
21 Natural History Study of Parathyroid Disorders Recruiting NCT04969926
22 PRIME Study: Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients Recruiting NCT05037461
23 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
24 Coordination of Rare Diseases at Sanford Recruiting NCT01793168
25 Endoscopic Ultrasound-guided Fine-needle Injection for Multiple Endocrine Neoplasia Type 1-related Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study Recruiting NCT05554744
26 Study and Monitoring of Multiple Endocrine Neoplasia Type 1 Recruiting NCT03966612
27 Study and Follow-up of Multiple Endocrine Neoplasia Type 1 Recruiting NCT03348501
28 Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients Recruiting NCT03048266
29 Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) Recruiting NCT03053999
30 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Recruiting NCT04028479 Systemic Treatment (T)
31 Genetic Modifying Factors and Pheochromocytomas in Multiple Endocrine Neoplasia Type 2 Recruiting NCT05158712
32 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Active, not recruiting NCT03043508
33 Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Active, not recruiting NCT03048279
34 Family Studies in Metabolic Diseases and Mineral Metabolism Active, not recruiting NCT00001345
35 An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC Terminated NCT03001349 Early Phase 1 Gallium Ga 68-Edotreotide
36 Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients Terminated NCT03044600

Search NIH Clinical Center for Multiple Endocrine Neoplasia, Type I

Cochrane evidence based reviews: multiple endocrine neoplasia type 1

Genetic Tests for Multiple Endocrine Neoplasia, Type I

Genetic tests related to Multiple Endocrine Neoplasia, Type I:

# Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia, Type 1 28 MEN1

Anatomical Context for Multiple Endocrine Neoplasia, Type I

Organs/tissues related to Multiple Endocrine Neoplasia, Type I:

MalaCards : Pituitary, Pancreas, Thyroid, Spinal Cord, Thymus, Pancreatic Islet, Kidney
ODiseA: Pituitary

Publications for Multiple Endocrine Neoplasia, Type I

Articles related to Multiple Endocrine Neoplasia, Type I:

(showing 6255, show less)
# Title Authors PMID Year
1
Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. 62 24 57 5
17879353 2008
2
Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. 62 24 57 5
14985373 2004
3
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. 62 24 57 5
11836268 2002
4
Characterization of mutations in patients with multiple endocrine neoplasia type 1. 62 24 57 5
9463336 1998
5
Somatic mutation of the MEN1 gene in parathyroid tumours. 62 24 57 5
9241276 1997
6
Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. 53 62 57 5
9709921 1998
7
Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. 53 62 57 5
9215689 1997
8
Effect of multiple endocrine neoplasia type 1 (MEN1) gene mutations on premature mortality in familial MEN1 syndrome with founder mutations. 62 57 5
15240620 2004
9
Germline mutations of the MEN1 gene in Korean families with multiple endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. 62 57 5
12791038 2003
10
A novel six-nucleotide insertion in exon 4 of the MEN1 gene, 878insCTGCAG, in three patients with familial insulinoma and primary hyperparathyroidism. 62 57 5
12417605 2002
11
Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. 62 57 5
12112656 2002
12
Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. 62 57 5
12050235 2002
13
Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. 62 57 5
11579199 2001
14
Familial isolated primary hyperparathyroidism--a multiple endocrine neoplasia type 1 variant? 53 62 24 5
11454510 2001
15
Identification of five novel germline mutations of the MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. 62 57 5
9832038 1998
16
Novel V184E MEN1 germline mutation in a Japanese kindred with familial hyperparathyroidism. 62 57 5
9843042 1998
17
Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. 62 57 5
9683585 1998
18
Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. 62 57 5
9554741 1998
19
Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. 62 57 5
9215690 1997
20
Positional cloning of the gene for multiple endocrine neoplasia-type 1. 62 57 5
9103196 1997
21
Variant multiple endocrine neoplasia I (MEN IBurin): further studies and non-linkage to HLA. 62 57 5
2857681 1985
22
Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). 62 24 5
26224587 2016
23
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. 62 24 5
24443791 2014
24
Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. 62 24 5
17158764 2006
25
Gonadotroph tumor associated with multiple endocrine neoplasia type 1. 62 24 5
15522929 2005
26
Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. 62 24 57
15531478 2004
27
Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. 62 24 57
15292304 2004
28
Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? 62 24 5
14641000 2003
29
Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. 62 24 5
12699448 2003
30
Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. 62 24 5
12213668 2002
31
Adrenal involvement in multiple endocrine neoplasia type 1. 62 24 5
12016472 2002
32
Guidelines for diagnosis and therapy of MEN type 1 and type 2. 62 24 57
11739416 2001
33
Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. 62 24 5
11134142 2000
34
Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. 62 24 57
9236523 1997
35
Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors. 57 5
6108714 1980
36
Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. 53 62 5
19074834 2008
37
Diagnosis by serendipity: Cushing syndrome attributable to cortisol-producing adrenal adenoma as the initial manifestation of multiple endocrine neoplasia type 1 due to a rare splicing site MEN1 gene mutation. 53 62 5
18753104 2008
38
Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. 53 62 5
16449969 2006
39
Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. 53 62 5
15870131 2005
40
A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. 53 62 5
15635078 2005
41
Direct binding of DNA by tumor suppressor menin. 53 62 5
15331604 2004
42
Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. 53 62 57
15333582 2004
43
Genetic screening methods for the detection of mutations responsible for multiple endocrine neoplasia type 1. 53 62 5
15464422 2004
44
Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. 53 62 5
15254225 2004
45
Unusual presentation of multiple endocrine neoplasia type 1 in a young woman with a novel mutation of the MEN1 gene. 53 62 5
15205994 2004
46
Prospective controlled trial of a standardized meal stimulation test in the detection of pancreaticoduodenal endocrine tumours in patients with multiple endocrine neoplasia type 1. 53 62 5
11578300 2001
47
Identification of MEN1 gene mutations in families with MEN 1 and related disorders. 53 62 5
10993647 2000
48
Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. 53 62 5
10849016 2000
49
MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1. 53 62 5
10664520 2000
50
Menin, the product of the MEN1 gene, is a nuclear protein. 53 62 57
9465067 1998
51
Menin mutations in patients with multiple endocrine neoplasia type 1. 53 62 5
9437237 1997
52
A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. 53 62 57
9253601 1997
53
Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes. 62 5
34183184 2022
54
Genomic profiling of multiple tissues in two patients with multiple endocrine neoplasia type 1. 62 5
33840689 2021
55
Whole genome sequencing of apparently mutation-negative MEN1 patients. 62 5
31658439 2020
56
True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. 62 5
31044390 2019
57
Granular Cell Pituitary Tumor in a Patient with Multiple Endocrine Neoplasia-1. 62 5
31275768 2019
58
Novel Mutations in Serbian MEN1 Patients: Genotype-phenotype Correlation. 62 5
30820182 2019
59
UMD-MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients From the French Population. 62 5
30339208 2019
60
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 62 5
31249555 2019
61
Germline mutation landscape of multiple endocrine neoplasia type 1 using full gene next-generation sequencing. 62 5
30324798 2018
62
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. 62 5
29497973 2018
63
Pancreatic hemi-agenesis in MEN1: A clinical report. 62 5
29174091 2018
64
When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism. 62 5
30364322 2018
65
Analysis of MEN1 c.482G>A (p.Gly161Asp) mutation in a pedigree with familial multiple endocrine neoplasia type 1. 62 5
29039523 2017
66
Primary hyperparathyroidism in young patients in Russia: high frequency of hyperparathyroidism-jaw tumor syndrome. 62 5
28870973 2017
67
Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary? 62 5
28321559 2017
68
Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. 62 5
28238068 2017
69
Late onset asymptomatic pancreatic neuroendocrine tumor - A case report on the phenotypic expansion for MEN1. 62 5
28736585 2017
70
Germline and somatic genetic changes in multicentric tumors obtained from a patient with multiple endocrine neoplasia type 1. 62 5
28503312 2017
71
Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. 62 5
29036195 2017
72
Multiple endocrine neoplasia type 1 (MEN1): An update of 208 new germline variants reported in the last nine years. 62 5
26767918 2016
73
Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1. 62 5
25824098 2015
74
EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. 62 5
25527055 2015
75
Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion. 62 5
25733923 2015
76
Genetic and epigenetic analysis in korean patients with multiple endocrine neoplasia type 1. 62 5
25309785 2014
77
Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. 62 5
24915123 2014
78
A rare case of hypoglycaemia due to insulinoma in an adolescent with acutely altered mental status. 62 5
24756045 2014
79
Insulinoma in childhood: clinical, radiological, molecular and histological aspects of nine patients. 62 5
24599222 2014
80
Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening. 62 5
23334809 2014
81
Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. 62 5
23321498 2013
82
MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. 62 5
23093699 2013
83
Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. 62 5
22470073 2012
84
Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. 62 5
22026581 2012
85
Impaired transforming growth factor-β (TGF-β) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1). 62 5
22275377 2012
86
Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. 62 5
22090276 2012
87
The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. 62 5
22327296 2012
88
A puzzling case of phospho-soda-induced hypocalcemia in a patient with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. 62 5
23154721 2012
89
A novel deletion of the MEN1 gene in a large family of multiple endocrine neoplasia type 1 (MEN1) with aggressive phenotype. 62 5
21627674 2011
90
Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. 62 5
21819486 2011
91
Unique gene expression profile associated with an early-onset multiple endocrine neoplasia (MEN1)-associated pituitary adenoma. 62 5
21917868 2011
92
Multiple endocrine neoplasia type 1 and adrenal Cushing's. 62 5
21369528 2011
93
The menin tumor suppressor protein is phosphorylated in response to DNA damage. 62 5
21264250 2011
94
The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. 62 5
21127195 2011
95
Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. 62 5
20660572 2010
96
Long-term follow-up of an 8-year-old boy with insulinoma as the first manifestation of a familial form of multiple endocrine neoplasia type 1. 62 5
21340165 2010
97
Application of genetic testing to define the surgical approach in a sporadic case of multiple endocrine neoplasia type 1. 62 5
21340156 2010
98
Multiple endocrine neoplasia type 1 (MEN1). 62 5
20833329 2010
99
Improvement in the care of multiple endocrine neoplasia type 1 through a regional multidisciplinary clinic. 62 5
20231234 2010
100
Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). 62 5
19953642 2010
101
Familial pituitary adenomas. 53 62 24
19522822 2009
102
Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. 62 5
19350320 2009
103
MEN1 gene and its mutations: basic and clinical implications. 62 5
19068082 2009
104
[Clinical and molecular features in a family with multiple endocrine neoplasia type-1 syndrome]. 62 5
19174080 2008
105
Gonadotroph adenoma in multiple endocrine neoplasia type 1. 53 62 24
18753103 2008
106
Gene symbol: MEN1. Disease: Multiple endocrine neoplasia 1. 62 5
20960638 2008
107
Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. 62 5
17555499 2007
108
Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. 62 5
17853334 2007
109
Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. 62 5
17623761 2007
110
Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation. 62 5
17766710 2007
111
Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. 62 5
17235589 2007
112
Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. 62 57
17179192 2007
113
Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. 62 5
17065424 2006
114
New splicing mutation of MEN1 gene affecting the translocation of menin to the nucleus. 62 5
17185897 2006
115
Characteristics of the Danish families with multiple endocrine neoplasia type 1. 62 5
16563611 2006
116
Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention. 53 62 24
16594911 2006
117
Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. 62 5
16430712 2006
118
Novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1. 62 5
15730416 2005
119
Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. 62 5
15670192 2005
120
Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. 62 5
15714081 2005
121
Homozygous loss of menin is well tolerated in liver, a tissue not affected in MEN1. 62 57
15672591 2004
122
Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism. 53 62 24
15292357 2004
123
Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. 62 5
15044367 2004
124
Recent advances in MEN1 gene study for pituitary tumor pathogenesis. 62 5
15281352 2004
125
Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. 62 57
14715834 2004
126
Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain. 62 5
14508515 2003
127
Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients. 62 5
12746426 2003
128
The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. 62 5
12509449 2003
129
Efficient mutation detection in MEN1 gene using a combination of single-strand conformation polymorphism (MDGA) and heteroduplex analysis. 62 5
12652570 2003
130
Genotype-phenotype analysis in multiple endocrine neoplasia type 1. 62 5
12049533 2002
131
Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired, hypophosphatemic osteomalacia. 62 57
11701736 2001
132
Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. 62 57
11549677 2001
133
The antral mucosa as a new site for endocrine tumors in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndromes. 62 57
11344233 2001
134
Multiple endocrine neoplasia type 1: new clinical and basic findings. 62 57
11295574 2001
135
Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. 62 57
11238532 2001
136
Founder effect in multiple endocrine neoplasia type 1 (MEN 1) in Finland. 62 5
11303512 2001
137
A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. 62 57
11158604 2001
138
Rare somatic inactivation of the multiple endocrine neoplasia type 1 gene in secondary hyperparathyroidism of uremia. 62 57
11095441 2000
139
A 5178-9g--> A splice donor site mutation in intron 4 of the MEN1 gene causing multiple endocrine neoplasia type 1 62 5
10861493 2000
140
Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. 62 5
10762295 2000
141
Molecular pathology of multiple endocrine neoplasia type I: two novel germline mutations and updated classification of mutations affecting MEN1 gene. 62 5
10617276 1999
142
Screening for MEN1 mutations in patients with atypical endocrine neoplasia. 62 5
10598193 1999
143
Multiple endocrine neoplasia type 1. 62 5
10730900 1999
144
Alternative genetic pathways in parathyroid tumorigenesis. 62 57
10523029 1999
145
Genetic and clinical analysis in 10 Spanish patients with multiple endocrine neoplasia type 1. 62 57
10439966 1999
146
Hibernomas are characterized by homozygous deletions in the multiple endocrine neoplasia type I region. Metaphase fluorescence in situ hybridization reveals complex rearrangements not detected by conventional cytogenetics. 62 57
10393837 1999
147
A novel splicing mutation (894-9 G --> A) of the MEN1 gene responsible for multiple endocrine neoplasia type 1. 62 5
10424788 1999
148
Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene. 62 57
10341092 1999
149
Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. 62 57
10022445 1999
150
MEN1 gene analysis in sporadic adrenocortical neoplasms. 62 57
9920087 1999
151
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. 62 5
9989505 1999
152
Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. 62 5
10090472 1999
153
[Germline mutations in the MEN1 gene: basis for predictive genetic screening and clinical management of multiple endocrine neoplasia type 1 (MEN1) families]. 62 5
9893679 1998
154
A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. 62 5
9792884 1998
155
MEN1 gene mutations in 12 MEN1 families and their associated tumors. 62 5
9820618 1998
156
Menin mutations in MEN1 patients. 62 5
9709985 1998
157
Alterations of the MEN1 gene in sporadic parathyroid tumors. 62 57
9709922 1998
158
Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. 62 57
9709976 1998
159
Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. 62 57
9543172 1998
160
Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. 62 5
9564891 1998
161
Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. 62 57
9506756 1998
162
Multiple endocrine neoplasia 1 gene alterations in MEN1-associated and sporadic lipomas. 62 57
9498491 1998
163
Analysis of recurrent germline mutations in the MEN1 gene encountered in apparently unrelated families. 62 5
9671267 1998
164
Five novel mutations in the familial multiple endocrine neoplasia type 1 (MEN1) gene. Mutations in brief no. 188. Online. 62 5
10660339 1998
165
Germline mutations of the MEN1 gene in Japanese kindred with multiple endocrine neoplasia type 1. 62 5
9439676 1997
166
A large multiple endocrine neoplasia type 1 family with clinical expression suggestive of anticipation. 62 5
9329390 1997
167
Construction of a 1.2-Mb sequence-ready contig of chromosome 11q13 encompassing the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. 62 57
9286704 1997
168
Definition of the minimal MEN1 candidate area based on a 5-Mb integrated map of proximal 11q13. The European Consortium on Men1, (GENEM 1; Groupe d'Etude des Néoplasies Endocriniennes Multiples de type 1). 62 57
8938448 1996
169
Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MEN1Burin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland. 62 57
7911003 1994
170
Two patients with Cushing's disease in a kindred with multiple endocrine neoplasia type I. 62 57
8099078 1993
171
A linkage map of mouse chromosome 19: definition of comparative mapping relationships with human chromosomes 10 and 11 including the MEN1 locus. 62 57
1358795 1992
172
Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. 62 57
1352309 1992
173
Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. 62 57
1352275 1992
174
Predictive testing for multiple endocrine neoplasia type 1 using DNA polymorphisms. 62 57
1348254 1992
175
Fine-scale mapping of the gene responsible for multiple endocrine neoplasia type 1 (MEN 1). 62 57
1734719 1992
176
A radiation hybrid map of the proximal long arm of human chromosome 11 containing the multiple endocrine neoplasia type 1 (MEN-1) and bcl-1 disease loci. 62 57
1684084 1991
177
Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. 62 57
1968641 1990
178
Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. 62 57
2568587 1989
179
Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. 62 57
2568586 1989
180
Localization of the genetic defect in multiple endocrine neoplasia type 1 within a small region of chromosome 11. 62 57
2565085 1989
181
Linkage analysis of multiple endocrine neoplasia type 1 with INT2 and other markers on chromosome 11. 62 57
2565877 1989
182
Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. 62 57
2894610 1988
183
Zollinger-Ellison syndrome. Current concepts in diagnosis and management. 62 57
3309661 1987
184
Nonidentical expressions of multiple endocrine neoplasia, type I, in identical twins. 62 57
2875227 1986
185
Cushing's syndrome in patients with the Zollinger-Ellison syndrome. 62 57
2872593 1986
186
Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type 1. 62 57
2871488 1986
187
Changing concepts in the presentation, diagnosis and management of the Zollinger-Ellison syndrome. 62 57
6137024 1983
188
A familial glucagonoma syndrome: genetic, clinical and biochemical features. 62 57
6112877 1981
189
A kindred with 5 cases of multiple endocrine adenomatosis type I. 62 57
6112202 1981
190
Hyperparathyroidism: a prerequisite for Zollinger-Ellison syndrome in multiple endocrine adenomatosis Type 1--report of a further family and a review of th literature. 62 57
6107954 1980
191
Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I. 62 57
37794 1979
192
Clinical significance of hyperparathyroidism in familial multiple endocrine adenomatosis type I (MEA I). 62 57
34999 1979
193
Prevalence of endocrine abnormalities in patients with the Zollinger-Ellison syndrome and in their families. 62 57
25580 1978
194
Multiple endocrine adenomatosis syndromes. 62 57
3102 1976
195
Hypergastrinemia in familial multiple endocrine adenomatosis. 62 57
4150177 1974
196
Familial nesidioblastosis as the predominant manifestation of multiple endocrine adenomatosis. 62 57
4400504 1972
197
Five families with multiple endocrine adenomatosis. 62 57
4401787 1972
198
Clinicopathologic conference. Multiple endocrine adenomatosis. 62 57
4186264 1969
199
Familial endocrine adenomatosis with associated Zollinger-Ellison syndrome. Wermer's syndrome. 62 57
4384624 1968
200
Clinical and genetic investigation of a large kindred with multiple endocrine adenomatosis. 62 57
4384073 1967
201
Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. 62 24
34636744 2021
202
Multiple Endocrine Neoplasia Type 1: Latest Insights. 62 24
33249439 2021
203
Quality of life in Italian patients with Multiple endocrine neoplasia type 1 (MEN 1): results of an extensive survey. 62 24
33407684 2021
204
Prevalence of Parathyroid Carcinoma and Atypical Parathyroid Neoplasms in 153 Patients With Multiple Endocrine Neoplasia Type 1: Case Series and Literature Review. 62 24
33101196 2020
205
Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs. 62 24
32695849 2020
206
Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1. 62 24
31521501 2019
207
Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature. 62 24
30721134 2019
208
Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome. 62 24
30481156 2019
209
Diagnosis of mosaic mutations in the MEN1 gene by next generation sequencing. 62 24
30444722 2019
210
Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature. 5
29455199 2018
211
Primary hyperparathyroidism in Chinese children and adolescents: A single-centre experience at Peking Union Medical College Hospital. 62 24
28833384 2017
212
Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels. 5
28818680 2017
213
Management impact: effects on quality of life and prognosis in MEN1. 62 24
28733468 2017
214
Management of a multiple endocrine neoplasia type 1 during pregnancy: A case report and review of the literature. 62 24
28471129 2016
215
Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group. 62 24
26751192 2016
216
Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'étude des Tumeurs Endocrines study. 62 24
26392472 2015
217
Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. 62 24
26165399 2015
218
Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it. 5
25291050 2015
219
Breast-cancer predisposition in multiple endocrine neoplasia type 1. 62 24
25099597 2014
220
Multiple endocrine neoplasia type 1 (MEN1). 62 24
23279763 2013
221
Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study. 62 24
23376981 2013
222
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). 62 24
22723327 2012
223
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. 62 24
22520146 2012
224
Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. 62 24
21950691 2012
225
The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. 62 24
22409234 2012
226
Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. 62 24
22084155 2012
227
Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. 62 24
22584706 2012
228
A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. 62 24
23091742 2012
229
Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. 62 24
19949948 2010
230
Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. 62 24
20585352 2010
231
Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. 62 24
19309299 2009
232
Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). 62 24
19294466 2009
233
Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. 62 24
19228930 2009
234
Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. 62 24
18755492 2009
235
Synchronous thymoma and thymic carcinoid in a woman with multiple endocrine neoplasia type 1: case report and review. 62 24
18996790 2008
236
Metastasis of carcinoid to the arch of the axis in a multiple endocrine neoplasia patient: a case report. 62 24
18037349 2008
237
Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. 62 24
18520436 2008
238
A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. 62 24
18270260 2008
239
Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. 62 24
18426829 2008
240
Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. 62 24
18300794 2008
241
Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. 62 24
18376196 2008
242
Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case. 62 24
19039643 2008
243
Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. 62 24
18172277 2008
244
Rapidly growing collagenomas in multiple endocrine neoplasia type I. 62 24
17188781 2007
245
Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. 62 24
17135306 2007
246
Living with multiple endocrine neoplasia type 1: decent care-insufficient medical and genetic information: a qualitative study of MEN 1 patients in a Swedish hospital. 62 24
17277996 2007
247
Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology. 62 24
17652799 2007
248
Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. 5
17576681 2007
249
Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. 62 24
16794390 2006
250
Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. 62 24
16680582 2006
251
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. 62 24
16699310 2006
252
Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. 62 24
16454829 2006
253
ACTH-secreting thymic carcinoid associated with multiple endocrine neoplasia type 1. 62 24
16368411 2006
254
Multiple endocrine neoplasia type I and Cushing's syndrome due to an aggressive ACTH producing thymic carcinoid. 62 24
16484744 2006
255
Primary peripancreatic lymph node gastrinoma in a woman with MEN1. 62 24
17013727 2006
256
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. 62 24
16415155 2006
257
Splicing in action: assessing disease causing sequence changes. 5
16199547 2005
258
Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. 62 24
15887103 2005
259
Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. 62 24
15713725 2005
260
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. 5
15753368 2005
261
Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. 62 24
15611976 2005
262
Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. 62 24
15563473 2005
263
Multiple endocrine neoplasia syndrome: genetic basis for clinical management. 62 24
15608505 2005
264
Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. 62 24
15606375 2005
265
Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. 62 24
15588237 2004
266
Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. 62 24
15517479 2004
267
Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. 62 24
15150273 2004
268
Ureteral leiomyoma causing hydronephrosis in Type 1 multiple endocrine neoplasia. 62 24
15144407 2004
269
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. 62 24
15168774 2004
270
Cushing's disease as the first clinical manifestation of multiple endocrine neoplasia type 1 (MEN1) associated with an R460X mutation of the MEN1 gene. 62 24
14678300 2004
271
Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. 62 24
14747767 2004
272
Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. 62 24
12649288 2003
273
The treatment of sporadic versus MEN1-related pituitary adenomas. 62 24
12755955 2003
274
Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. 62 24
12808627 2003
275
The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. 62 24
12656664 2003
276
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. 62 24
12629087 2003
277
Carcinoid--a comprehensive review. 62 24
14690153 2003
278
Molecular pathogenesis of primary hyperparathyroidism. 62 24
12412775 2002
279
Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. 62 24
12100081 2002
280
Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. 62 24
11549605 2001
281
Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. 62 24
11037994 2000
282
The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. 5
10490816 1999
283
Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. 5
10445857 1999
284
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. 57
10080607 1999
285
Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. 62 24
10548885 1999
286
Multiple endocrine neoplasia--syndromes of the twentieth century. 57
9709920 1998
287
Pathogenesis of ECL cell tumors in humans. 62 24
10461358 1998
288
Statistical features of human exons and their flanking regions. 5
9536098 1998
289
Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. 5
9242375 1997
290
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 5
9012462 1997
291
RET activation by germline MEN2A and MEN2B mutations. 5
8570194 1995
292
Allelic loss from chromosome 11 in parathyroid tumors. 62 24
1360870 1992
293
Hereditary pituitary prolactinomas: a new rat model. 57
3059738 1988
294
Multiple endocrine neoplasia: search for the oncogenic trigger. 57
2871489 1986
295
Genetic aspects of multiple endocrine neoplasia. 57
6144286 1984
296
Prolactinomas as part of the multiple endocrine neoplastic syndrome type 1. 57
6837595 1983
297
Zollinger-Ellison syndrome. 57
7044271 1982
298
Conservative management of the Zollinger-Ellison syndrome. Ectopic gastrin production by an ovarian cystadenoma. 57
7365959 1980
299
Coexistence of bilateral pheochromocytoma and pancreatic islet cell tumor: report of a case and review of the literature. 57
215301 1978
300
Diurnal variations in the influence of the ultimobranchial glands on calcium homeostasis in the frog (Rana pipiens). 5
215689 1978
301
The Zollinger-Ellison syndrome--23 years later. 57
686901 1978
302
A reappraisal of clinical, roentgenographic, and endoscopic features of the Zollinger-Ellison syndrome. 57
625140 1978
303
H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy. 57
22304 1977
304
Canine Zollinger-Ellison syndrome. 57
187526 1977
305
Treatment of Zollinger-Ellison syndrome with streptozotocin. 57
131910 1976
306
Zollinger-Ellison syndrome associated with ovarian mucinous cystadenocarcinoma. 57
1152863 1975
307
Parathyroid carcinoma in familial hyperparathyroidism. 57
4372885 1974
308
Genetic aspects of the Z-E syndrome: prospective studies in two kindred; antral gastrin cell hyperplasia. 57
4342160 1972
309
Zollinger-Ellison syndrome in a nine-year-old child: a case report and review of the entity in childhood. 57
5547875 1971
310
A case of the Zollinger-Ellison syndrome associated with hyperplasia of salivary and Brunner's glands. 57
4320926 1970
311
Nesidioblastosis in familial endocrine adenomatosis. 57
4387956 1969
312
Zollinger-Ellison syndrome. An analysis of twenty-five cases. 57
4386328 1968
313
The Zollinger-Ellison syndrome updated. 57
4885837 1967
314
Zollinger-Ellison syndrome with interesting variations. Report of twelve cases including one of carcinoid of the duodenum. 57
4288594 1966
315
THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES. 57
14206854 1964
316
FAMILIAL MULTIPLE ENDOCRINE ADENOMA-PEPTIC ULCER COMPLEX. 57
14183520 1964
317
FAMILIAL HYPERPARATHYROIDISM. A KINDRED INVOLVING ELEVEN CASES, WITH A DISCUSSION OF PRIMARY CHIEF-CELL HYPERPLASIA. 57
14110030 1964
318
FAMILIAL ENDOCRINE ADENOMATOSIS. A FAMILY WITH HYPERINSULINISM AS THE PREDOMINANT MANIFESTATION. 57
14056823 1963
319
The association of bronchial carcinoid and pluriglandular adenomatosis. 57
14007148 1962
320
Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 57
13259432 1955
321
Genetic aspects of adenomatosis of endocrine glands. 57
13138607 1954
322
Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies. 24
31244908 2019
323
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. 24
26742109 2016
324
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. 24
25014687 2014
325
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. 24
24504504 2014
326
Primary hyperparathyroidism in pregnancy. 24
23670708 2013
327
Glucagonoma syndrome: a case report. 24
21859461 2011
328
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. 24
21349418 2011
329
Targeted radiotherapy with radiolabeled somatostatin analogs. 24
21349419 2011
330
Everolimus for advanced pancreatic neuroendocrine tumors. 24
21306238 2011
331
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. 24
21306237 2011
332
CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism. 53 62
19705144 2010
333
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. 24
19704057 2009
334
The epidemiology and genetics of pituitary adenomas. 53 62
19945022 2009
335
Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. 53 62
19491073 2009
336
Association of parathyroid adenoma and pregnancy with preeclampsia. 24
19531594 2009
337
Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. 53 62
19654304 2009
338
Multiple endocrine neoplasias: advances and challenges for the future. 53 62
19522821 2009
339
Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition. 53 62
19474519 2009
340
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. 53 62
19238077 2009
341
Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma. 53 62
19170121 2009
342
Genetic, molecular and clinical features of familial isolated pituitary adenomas. 53 62
19407507 2009
343
Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. 53 62
18673462 2009
344
Menin: the protein behind the MEN1 syndrome. 53 62
20175450 2009
345
Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. 53 62
19153518 2009
346
[Familial pituitary adenomas]. 53 62
18990538 2009
347
The role of menin in parathyroid tumorigenesis. 53 62
20175455 2009
348
Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. 53 62
19075677 2008
349
Update on the treatment of pituitary adenomas: familial and genetic considerations. 53 62
19170361 2008
350
Menin regulates endocrine diseases by controlling histone modification and gene transcription. 53 62
18752793 2008
351
Possible association between Carney complex and multiple endocrine neoplasia type 1 phenotypes. 53 62
19169494 2008
352
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. 53 62
18485119 2008
353
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. 53 62
18598942 2008
354
Insulinoma cell calcium-sensing receptor influences insulin secretion in a case with concurrent familial hypocalciuric hypercalcemia and malignant metastatic insulinoma. 53 62
18430790 2008
355
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. 24
18456740 2008
356
Molecular and trophic mechanisms of tumorigenesis. 53 62
18226729 2008
357
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. 53 62
17803708 2008
358
Pheochromocytoma: an update on genetics and management. 53 62
18045948 2007
359
Novel human pathological mutations. Gene symbol: MEN1. Disease: MEN1, Multiple endocrine neoplasia, type 1. 53 62
18350655 2007
360
Novel association of duodenal gastrinoma and atrophic gastritis: case report and literature review. 53 62
18194935 2007
361
Menin is required in cranial neural crest for palatogenesis and perinatal viability. 53 62
17927973 2007
362
The clinical, pathological, and genetic features of familial isolated pituitary adenomas. 53 62
17893250 2007
363
No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. 53 62
17914118 2007
364
Interaction of MLL amino terminal sequences with menin is required for transformation. 24
17671196 2007
365
Global expression profiling of murine MEN1-associated tumors reveals a regulatory role for menin in transcription, cell cycle and chromatin remodelling. 53 62
17455252 2007
366
Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. 53 62
17639062 2007
367
The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. 53 62
17299066 2007
368
Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. 53 62
17613552 2007
369
Anatomic and functional imaging of metastatic carcinoid tumors. 24
17374863 2007
370
In search of tumor suppressing functions of menin. 53 62
17222504 2007
371
Menin and its interacting proteins: elucidation of menin function. 53 62
16997566 2006
372
A whole MEN1 gene deletion flanked by Alu repeats in a family with multiple endocrine neoplasia type 1. 53 62
17000701 2006
373
Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations. 53 62
16304664 2006
374
Production, secretion, and biological activity of the C-terminal flanking peptide of human progastrin. 53 62
17101322 2006
375
Clinical characterization of familial isolated pituitary adenomas. 53 62
16787992 2006
376
Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. 53 62
16886955 2006
377
Expression and functional analysis of menin in a multiple endocrine neoplasia type 1 (MEN1) patient with somatic loss of heterozygosity in chromosome 11q13 and unidentified germline mutation of the MEN1 gene. 53 62
16943588 2006
378
Menin links estrogen receptor activation to histone H3K4 trimethylation. 53 62
16651450 2006
379
Pituitary adenoma predisposition caused by germline mutations in the AIP gene. 24
16728643 2006
380
MEN1 family with a novel frameshift mutation. 53 62
16794369 2006
381
Growth hormone-secreting tumors: genetic aspects and data from animal models. 53 62
17047380 2006
382
Pituitary pathology in patients with Carney Complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. 53 62
17001464 2006
383
Genetics and proteomics of pituitary tumors. 53 62
16311409 2005
384
Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. 24
16253893 2005
385
Ghrelin expression in neuroendocrine tumours of the gastrointestinal tract with multiple endocrine neoplasia type 1. 53 62
16278790 2005
386
Treatment of Zollinger-Ellison syndrome. 53 62
16222731 2005
387
Chromosomal instability predicts metastatic disease in patients with insulinomas. 53 62
15947114 2005
388
A germline mutation in a Thai family with familial multiple endocrine neoplasia type 1. 53 62
15962670 2005
389
An overview of the epidemiology and genetics of acromegaly. 53 62
16625848 2005
390
Surgical management of primary hyperparathyroidism: the case for giving up quick intraoperative PTH assay in favor of routine PTH measurement the morning after. 24
15570200 2004
391
Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. 53 62
15031321 2004
392
JunD-menin interaction regulates c-Jun-mediated AP-1 transactivation. 53 62
15256779 2004
393
Familial acromegaly. 53 62
15135786 2004
394
Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). 53 62
15082967 2004
395
Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. 53 62
15126560 2004
396
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. 53 62
15104570 2004
397
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. 53 62
15126555 2004
398
Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. 53 62
15026366 2004
399
Isolated familial somatotropinoma. 53 62
15761658 2004
400
Endocrine tumor syndromes in infancy and childhood. 53 62
15640547 2004
401
Pituitary pathology in Carney complex patients. 53 62
15761655 2004
402
Pathology and molecular genetics of the pituitary gland in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). 53 62
15281351 2004
403
[Multiple endocrine neoplasias. Recent advances in clinical and genetic diagnosis]. 53 62
14604749 2003
404
[Multiple endocrine neoplasia type 1. MEN1-- Wermer syndrome]. 53 62
15067750 2003
405
Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. 53 62
14559791 2003
406
HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. 53 62
12960210 2003
407
In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. 53 62
12915685 2003
408
Isolated familial somatotropinomas: clinical and genetic considerations. 53 62
12813918 2003
409
Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. 53 62
12534356 2003
410
The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. 53 62
12459032 2002
411
Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor nm23. 53 62
12145286 2002
412
Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. 53 62
12239610 2002
413
The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. 53 62
12021209 2002
414
Genetic analysis of lithium-associated parathyroid tumors. 53 62
11980616 2002
415
Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. 53 62
11966738 2002
416
Determination of allelic deletion of multiple endocrine neoplasm type 1 (MEN1) gene in acute myeloid leukemia (AML) by application of FISH-TSA technique. 53 62
12210500 2002
417
Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. 53 62
12181718 2002
418
[Gigantism: a mystery explained]. 24
12371275 2002
419
Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. 24
11807402 2002
420
Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse. 53 62
11712086 2001
421
Homozygous inactivation of the MEN1 gene as a specific somatic event in a case of secondary hyperparathyroidism. 53 62
11580998 2001
422
Multiple endocrine neoplasia type 1 and adrenal lesions. 53 62
11435815 2001
423
Predictive genetic screening and clinical findings in multiple endocrine neoplasia type I families. 53 62
11369988 2001
424
Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. 53 62
11302744 2001
425
Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes in isolated familial acromegaly. 53 62
11158006 2001
426
Diagnostic value of plasma chromogranin A in neuroendocrine tumours. 53 62
11204811 2001
427
Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? 53 62
11114630 2000
428
Multiple endocrine neoplasia (MEN)--an overview and case report--patient with sporadic bilateral pheochromocytoma, hyperparathyroidism and marfanoid habitus. 53 62
11205236 2000
429
Complementary DNA structure and genomic organization of Drosophila menin. 53 62
11064160 2000
430
Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). 53 62
11061550 2000
431
Interstitial deletion of 11q13 sequences in HeLa cells. 53 62
10959095 2000
432
Treatment of type II gastric carcinoid tumors with somatostatin analogues. 24
10954763 2000
433
Novel deletional mutation of the MEN 1 gene in a kindred with multiple endocrine neoplasia type 1. 53 62
10945663 2000
434
[Multiple endocrine neoplasia: a clinical model for applying molecular genetic techniques]. 53 62
11050843 2000
435
Internally shortened menin protein as a consequence of alternative RNA splicing due to a germline deletion in the multiple endocrine neoplasia type 1 gene. 53 62
10812010 2000
436
Multiple endocrine neoplasias. 53 62
10805954 2000
437
Absence of somatic RET gene mutation in sporadic parathyroid tumors and hyperplasia secondary to uremia, and absence of somatic Men1 gene mutation in MEN2A-associated hyperplasia. 53 62
10915003 2000
438
A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. 53 62
10963041 2000
439
Lack of MEN1 gene mutations in 27 sporadic insulinomas. 53 62
10759881 2000
440
Expression analysis of endogenous menin, the product of the multiple endocrine neoplasia type 1 gene, in cell lines and human tissues. 53 62
10709111 2000
441
Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review. 53 62
11228931 2000
442
Morphological, molecular, and prognostic aspects of gastric endocrine tumors. 53 62
10738315 2000
443
Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. 53 62
10690880 2000
444
Genetic, clinical, and biochemical analysis of unrelated Spanish families with multiple endocrine neoplasia type I. 53 62
11419921 2000
445
Daily follow-up of serum parathyroid hormone and calcium after surgery for primary hyperparathyroidism. 24
10604157 1999
446
Adult-onset angiofibroma and multiple endocrine neoplasia type I. 53 62
10534680 1999
447
Structure and distribution of rat menin mRNA. 53 62
10612420 1999
448
Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies. 53 62
10595737 1999
449
Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in the MEN1 gene. 53 62
10441003 1999
450
Review: multiple endocrine neoplasia type 1, sporadic neuroendocrine tumors, and MENIN. 53 62
10565680 1999
451
Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. 53 62
10443665 1999
452
Mechanisms of multiple endocrine neoplasia type 1: evidence for regulation of the AP-1 family of transcription factors by menin. 53 62
10407216 1999
453
Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. 53 62
10378509 1999
454
Adrenocortical tumors: recent advances in basic concepts and clinical management. 53 62
10357696 1999
455
Nuclear/cytoplasmic localization of the multiple endocrine neoplasia type 1 gene product, menin. 53 62
10092066 1999
456
Premature centromere division in patients with multiple endocrine neoplasia type 1. 53 62
10087948 1999
457
Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. 53 62
10396361 1999
458
Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene, men1. 53 62
9893060 1999
459
Pancreatic endocrine tumors: recent advances. 24
10436815 1999
460
Hyperparathyroidism and pregnancy. 24
10037311 1999
461
Treatment of prolactinomas. 24
9814831 1998
462
The MEN-1 gene is rarely down-regulated in pituitary adenomas. 53 62
9745428 1998
463
Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN1 gene in sporadic pituitary adenomas. 53 62
9709923 1998
464
Comparative genomic hybridization studies in tumours from a patient with multiple endocrine neoplasia type 1. 53 62
9724078 1998
465
Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. 53 62
9598800 1998
466
Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. 53 62
9626148 1998
467
The search for the MEN1 gene. The European Consortium on MEN-1. 53 62
9681841 1998
468
Menin mutations in the diagnosis and prediction of multiple endocrine neoplasia type 1. 53 62
9641896 1998
469
Human ZFM1 protein is a transcriptional repressor that interacts with the transcription activation domain of stage-specific activator protein. 53 62
9506990 1998
470
[A case of multiple endocrine neoplasia type I with primary hyperparathyroidism, prolactin secreting pituitary microadenoma and gastrin secreting duodenal carcinoid]. 53 62
9465604 1997
471
The germinal center kinase gene and a novel CDC25-like gene are located in the vicinity of the PYGM gene on 11q13. 53 62
9341881 1997
472
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1). 53 62
9272177 1997
473
Exclusion of ZFM1 as a candidate gene for multiple endocrine neoplasia type 1 (MEN1). 53 62
9150722 1997
474
Exclusion of the phosphatidylinositol-specific phospholipase C beta 3 (PLC beta 3) gene as candidate for the multiple endocrine neoplasia type 1 (MEN 1) gene. 53 62
9003511 1997
475
Gastrointestinal endocrine tumours. Pathology. 53 62
9113312 1996
476
[New etiopathogenic, clinical and therapeutic findings in multiple endocrine neoplasia type 1]. 53 62
8924487 1996
477
Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. 53 62
8675591 1996
478
Gs alpha mutation may be uncommon in patients with multiple endocrine neoplasia type 1. 53 62
8964883 1996
479
Molecular genetics of primary and secondary hyperparathyroidism. 53 62
8981014 1996
480
Hyperparathyroidism of multiple endocrine neoplasia type 1: candidate gene and parathyroid calcium sensing protein expression. 53 62
7491535 1995
481
[Multiple endocrine neoplasia]. 53 62
7752481 1995
482
Hypergastrinemia and gastric enterochromaffin-like cells. 53 62
7762739 1995
483
Presence of somatostatin receptors negatively coupled to adenylate cyclase in ectopic growth hormone-releasing hormone- and alpha-subunit-secreting tumors from acromegalic patients responsive to octreotide. 53 62
7962343 1994
484
Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I. 53 62
7846920 1994
485
Management of individual tumor syndromes. Pituitary neoplasia. 53 62
7913028 1994
486
Clinical management of gastric carcinoid tumors. 53 62
7698542 1994
487
Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. 53 62
7906100 1994
488
Peptide alpha-amidation activity in human plasma: relationship to gastrin processing. 53 62
8102327 1993
489
Isolation of 1001 new markers from human chromosome 11, excluding the region of 11p13-p15.5, and their sublocalization by a new series of radiation-reduced somatic cell hybrids. 53 62
1354639 1992
490
Studies in a kindred with parathyroid carcinoma. 53 62
1639936 1992
491
Molecular genetic mapping of the multiple endocrine neoplasia type 1 locus. 53 62
1362397 1992
492
Patterns of gastrin secretion in patients with nonfunctioning pituitary adenomas. 53 62
1802924 1991
493
Allele loss on chromosome 11 in a pituitary tumor from a patient with multiple endocrine neoplasia type 1. 53 62
1680115 1991
494
Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. 53 62
2347900 1990
495
Wrist pulse signal based vascular age calculation using mixed Gaussian model and support vector regression. 62
35529250 2022
496
Characterization and distribution of HIV-infected cells in semen. 62
35253610 2022
497
High blood pressure screening in pharmacies during May Measurement Month campaigns in Switzerland. 62
35699311 2022
498
When Cisgender, Heterosexual Men Feel Attracted to Transgender Women: Sexuality-Norm Violations Lead to Compensatory Anti-Gay Prejudice. 62
34185626 2022
499
Correlates of Bystander Intervention Among Heavy Drinking College Men. 62
35946125 2022
500
Online digital storytelling video on promoting men's intentions to seek counselling for depression: The role of empathy. 62
34088244 2022
501
Systematic detection of mosaicism by using digital NGS reveals three new MEN1 mosaicisms. 62
36112497 2022
502
Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor. 62
36107237 2022
503
ASO Visual Abstract: Long-Term Outcomes of Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms. 62
36109415 2022
504
Comparison Between Sporadic and Multiple Endocrine Neoplasia Type 1-Associated Insulinoma. 62
35752874 2022
505
Long-Term Outcomes for Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms. 62
35963905 2022
506
Invited Commentary: Less than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis. 62
36042033 2022
507
Less Than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis. 62
35767091 2022
508
Update on the clinical management of multiple endocrine neoplasia type 1. 62
35319130 2022
509
Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors. 62
36111275 2022
510
Multiple Endocrine Neoplasia Type 1 62
30725665 2022
511
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms. 62
36197786 2022
512
Leukocyte telomere length, allelic variations in related genes and risk of coronary heart disease in people with long-standing type 1 diabetes. 62
36221106 2022
513
Germline CDKN1B variant type and site are associated with phenotype in MEN4. 62
36256846 2022
514
Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature. 62
36271606 2022
515
Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations that Improve the Clinical Management of Pancreatic Cysts. 62
36209796 2022
516
Genetics of Pancreatic Neuroendocrine Tumors. 62
36154786 2022
517
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2. 62
35900839 2022
518
Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival. 62
36048542 2022
519
Lean body mass and the cardiovascular system constitute a female-specific relationship. 62
36260693 2022
520
C282Y/H63D Compound Heterozygosity Is a Low Penetrance Genotype for Iron Overload-related Disease. 62
36196271 2022
521
A Vignette Study Analyzing Contextual Factors that Influence Emerging Adults' Definitions of Virginity Loss in German-Speaking Countries. 62
34128744 2022
522
Prioritizing Flexibility, Human Connection, and Representation: Findings from the Qualitative Process Evaluation of the Special Projects of National Significance Black Men Who Have Sex with Men Initiative. 62
36178385 2022
523
The accuracy of ten common resting metabolic rate prediction equations in men and women collegiate athletes. 62
36168819 2022
524
Increasing trend in enterococcal bacteraemia and vancomycin resistance in a tertiary care hospital in Croatia, 2017-2021. 62
36240424 2022
525
Self-Perceived and Self-Tested Endurance: Associations with Objective Measures. 62
35678080 2022
526
Health Care Consumption, Psychiatric Diagnoses, and Pharmacotherapy 1 and 2 Years Before and After Newly Diagnosed HIV: A Case-Control Study Nested in The Greater Stockholm HIV Cohort Study. 62
36044611 2022
527
Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. 62
36270819 2022
528
Effect of Footwear on the Biomechanics of Loaded Back Squats to Volitional Exhaustion in Skilled Lifters. 62
33927116 2022
529
ABCL-179 Primary Cranial Vault Lymphoma: Review of Cases Diagnosed at a General Hospital. 62
36164060 2022
530
"I've Learned to Convert My Sensations into Sounds": Understanding During-Sex Sexual Communication. 62
36269285 2022
531
Cannabis Use Patterns and Related Health Outcomes Among Spanish Speakers in the United States and Internationally. 62
36187412 2022
532
Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. 62
36066519 2022
533
Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. 62
36088949 2022
534
Pasteurized Akkermansia muciniphila Reduces Fat Accumulation via nhr-49-Mediated Nuclear Hormone Signaling Pathway in Caenorhabditis elegans. 62
36234692 2022
535
Validation of StepTest4all for Assessing Cardiovascular Capacity in Young Adults. 62
36141547 2022
536
Lymphadenopathy after COVID-19 vaccination in patients with endocrine cancer: two case reports. 62
36112088 2022
537
Sex difference in human olfactory sensitivity is associated with plasma adiponectin. 62
35868172 2022
538
Gender differences in health-related quality of life and psychological distress among coronary patients: Does comorbidity matter? Results from the ESC EORP EUROASPIRE V registry. 62
36087631 2022
539
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. 62
35843248 2022
540
Do follicle-stimulating hormone receptor polymorphisms in infertile men influence intracytoplasmic sperm injection outcomes? A prospective cohort study. 62
36134751 2022
541
Boys Round Here: The Relationship Between Masculine Honor Ideology, Aggressive Behavior, Race, and Regional Affiliation. 62
36068948 2022
542
Resistance exercise differentially alters extracellular vesicle size and subpopulation characteristics in healthy men and women: an observational cohort study. 62
35816651 2022
543
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort. 62
36000082 2022
544
Safety and tolerability of progesterone treatment for women with cocaine use disorder: a pilot treatment trial. 62
36095308 2022
545
The Roots and Fruits of Masculinity: Social Antecedents and Sexual Relationship Consequences of Young Men's Adherence to Masculine Norms. 62
35316111 2022
546
Particularities of Catheter Ablation in Women with Atrial Fibrillation and Associated Ischemic Heart Disease. 62
36233431 2022
547
Sex-Specific Associations between Serum Ferritin and Osteosarcopenic Obesity in Adults Aged over 50 Years. 62
36235680 2022
548
Examining the Association between Racialized Economic Threat and White Suicide in the United States, 2000-2016. 62
35034482 2022
549
Do Men and Women Have a Different Association between Fear-Avoidance and Pain Intensity in Chronic Pain? An Experience Sampling Method Cohort-Study. 62
36233383 2022
550
The Prevalence of Depression Symptoms and Their Socioeconomic and Health Predictors in a Local Community with a High Deprivation: A Cross-Sectional Studies. 62
36142069 2022
551
Pain and alcohol consumption in virtual reality. 62
36174144 2022
552
Incidence, Characteristics, and Outcomes of Ventricular Fibrillation Complicating Acute Myocardial Infarction in Women Admitted Alive in the Hospital. 62
36017613 2022
553
The Association between Perpetuation of Intimate Partner Violence and Family Support on Couples with an Incarcerated Partner. 62
36231467 2022
554
Supervised pelvic floor muscle exercise is more effective than unsupervised pelvic floor muscle exercise at improving urinary incontinence in prostate cancer patients following radical prostatectomy - a systematic review and meta-analysis. 62
34550846 2022
555
Myocardial uptake of 68Ga-DOTATATE: correlation with cardiac disease and risk factors. 62
34713716 2022
556
Radiological Features of Zollinger-Ellison Syndrome: A Report of Two Cases. 62
36177273 2022
557
Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup. 62
36139607 2022
558
An Asymptomatic Case With MEN1 Slipping Through Genetic Screening by SNV-dependent Allelic Dropout. 62
35965945 2022
559
Genetic Dissection of Primary Aldosteronism in a Patient with MEN1 and Ipsilateral Adrenocortical Carcinoma and Adenoma. 62
36179244 2022
560
Early Detection of Relapse by ctDNA Sequencing in a Patient with Metastatic Thymic Tumor and MEN1 Mosaicism. 62
35904487 2022
561
Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregut-like profile. 62
35681273 2022
562
Genotype-Phenotype Correlations in Asian Indian Children and Adolescents with Primary Hyperparathyroidism. 62
35567607 2022
563
May the robotic approach expand the indications for redo surgery in recurrent pNETs in Multiple Neuroendocrine Neoplasia type 1? 62
36158249 2022
564
Mutational landscape of non-functional adrenocortical adenomas. 62
35731037 2022
565
Intraoperative Ultrasound Guided Laparoscopic Spleen-Preserving Distal Pancreatectomy for Primitive Neuroendocrine Tumors in a Pediatric Patient With MEN-1. 62
35471864 2022
566
Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas. 62
36085291 2022
567
Parathyroid carcinoma: Single centre experience. 62
35120263 2022
568
Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1. 62
35696052 2022
569
Dietary Manganese Intake and Risk of Liver Cancer in Japanese Men and Women: The JACC Study. 62
36047063 2022
570
Health-Related Quality of Life (HRQoL) and the Effect on Outcome in Patients Presenting with Coronary Artery Disease and Treated with Percutaneous Coronary Intervention (PCI): Differences Noted by Sex and Age. 62
36079161 2022
571
Revisiting the Evidence for Routine Transcervical Thymectomy for the Prevention of Thymic Carcinoid Tumours in MEN-1 Patients. 62
36103839 2022
572
Multiple endocrine neoplasia type 1 and pancreatic neuroendocrine tumour. Laparoscopic approach. 62
36064172 2022
573
Multiple endocrine neoplasia type 1 with suspicion of Zollinger Ellison syndrome in a family with history of renal stones and hypercalcemia in a limited resource setting: a case report. 62
36176950 2022
574
Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study. 62
35833229 2022
575
Clinical features and postoperative survival in patients with sporadic versus multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: An international cohort study. 62
35577612 2022
576
Synchronous Parathyroidectomy and Extended Thymectomy in Multiple Endocrine Neoplasia Type 1. 62
34921818 2022
577
Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. 62
35976056 2022
578
Genetic and Epigenetic Pathogenesis of Acromegaly. 62
36010855 2022
579
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. 62
36038743 2022
580
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. 62
36245271 2022
581
Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors. 62
35915373 2022
582
Familial Hyperparathyroidism: A Diagnostic and Treatment Challenge in Saudi Arabia. 62
36176852 2022
583
68Ga-DOTATATE PET/CT imaging for insulinoma in MEN1 patient with endogenous hyperinsulinemic hypoglycemia: A case report. 62
36042606 2022
584
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells. 62
35583188 2022
585
Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity. 62
35941657 2022
586
Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin. 62
35954231 2022
587
Loss of MEN1 leads to renal fibrosis and decreases HGF-Adamts5 pathway activity via an epigenetic mechanism. 62
35968938 2022
588
Canadian Gastroenterology Career Pathway Experiences: Exploring the Gender Divide. 62
35919764 2022
589
Who is at Risk? Social Support, Relationship Dissolution, and Illness in a Rural Context. 62
36059856 2022
590
Sex Differences in Long-Term Mortality of Patients with Hypertensive Crisis Visiting the Emergency Department. 62
34860590 2022
591
Physical activity and health-related quality of life in men and women with hip and/or knee osteoarthritis before and after a supported self-management programme - a prospective observational study. 62
33761294 2022
592
Association of Handgrip Strength in Various Disabilities in Korean Adults over 50 Years Old: A Nationwide Cross-Sectional Study. 62
35955100 2022
593
High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma. 62
35698921 2022
594
Male-Type Depression Mediates the Relationship between Avoidant Coping and Suicidal Ideation in Men. 62
36078589 2022
595
Association of Diet, Body Mass Index, and Lifestyle on the Gastrointestinal Health Risk in a Sample of Adults. 62
36078285 2022
596
The Role of Minority Stressors in Digital Dating Abuse Victimization and Perpetration among Sexual Minority Men. 62
36000406 2022
597
Psychometric properties of Spanish-language MMPI-3 scores in a Puerto Rican parental fitness evaluation setting. 62
35511513 2022
598
Do Early-Life Social, Behavioral, and Health Exposures Increase Later-Life Arthritis Incidence? 62
34664538 2022
599
Long-term Risk of Bleeding and Ischemic Events After Ischemic Stroke or Transient Ischemic Attack in Young Adults. 62
35654598 2022
600
Interpersonal Trauma Among Women and Men Receiving Buprenorphine in Outpatient Treatment for Opioid Use Disorder. 62
34894888 2022
601
Is Obesity Associated with Lower Mini Mental Test Scores among Elderly? A Cross Sectional Study. 62
34283003 2022
602
Gender-Egalitarian Attitudes and Assortative Mating by Age and Education. 62
35966361 2022
603
Place of residence, gender, month of birth and age influence on the concentration of specific IgE antibodies in serum. The Epidemiology of Allergic Diseases in Poland (ECAP survey): part three. 62
36090731 2022
604
How race and gender shape the development of social prototypes in the United States. 62
34941345 2022
605
Stereotactic Radiosurgery for Benign Cavernous Sinus Meningiomas: A Multicentre Study and Review of the Literature. 62
36011041 2022
606
Interaction of sex and diabetes in Asian patients with heart failure with mildly reduced left ventricular ejection fraction. 62
36047522 2022
607
Endobronchial Valve Treatment of Tuberculous Cavities in Patients with Multidrug-Resistant Pulmonary Tuberculosis: A Randomized Clinical Study. 62
36015021 2022
608
The Impact of the Metabolic Syndrome and Its Components on Resting Energy Expenditure. 62
36005594 2022
609
Patient Management in the Emergency Department during a COVID-19 Pandemic. 62
36011113 2022
610
Evaluation of the Satisfaction of Patients Seen in the Dermatology Department of a Spanish Tertiary Hospital. 62
36011218 2022
611
Vascular Reactions of the Diving Reflex in Men and Women Carrying Different ADRA1A Genotypes. 62
36012699 2022
612
A Pilot Study Testing A New Visual Stimuli Database for Probing Men's Gender Role Conflict: GRASP (Gender Role Affective Stimuli Pool). 62
35917153 2022
613
Adipose and Skeletal Muscle Expression of Adiponectin and Liver Receptor Homolog-1 With Weight Loss and Aerobic Exercise. 62
35854979 2022
614
Convergent Validity and Test-Retest Reliability of the Unsupported Upper Limb Exercise Test in Patients with Chronic Neck Pain. 62
35473433 2022
615
Expression of decitabine-targeted oncogenes in meningiomas in vivo. 62
35445910 2022
616
Thumb Reconstruction Using Transfer of the Ring Finger Without Vascular Anastomosis. 62
34454778 2022
617
Subtypes of Asthma and Cold Weather-Related Respiratory Symptoms. 62
35886638 2022
618
Clinical and pathological profile of gastric neuroendocrine tumors. 62
35900481 2022
619
[Comparison of criteria for metabolically healthy overweight/obesity in Shanghai Changfeng study]. 62
35764560 2022
620
Men have eating disorders too: an analysis of online narratives posted by men with eating disorders on YouTube. 62
34402402 2022
621
Continuing challenges of primary neuroendocrine tumours of the thymus: A concisereview. 62
35922282 2022
622
Better In Vitro Tools for Exploring Chlamydia trachomatis Pathogenesis. 62
35888153 2022
623
Different Factors Are Associated With Sex Hormones and Leydig Cell Function in Israelis and Palestinians in Jerusalem. 62
35815720 2022
624
Past Bullying Victimization Experiences and Current Sexual Risk Taking among Emerging Adults. 62
34904930 2022
625
[Meta analysis on mumps virus seroprevalence and evaluation of immunization effect in Chinese healthy population]. 62
35899355 2022
626
Muscle Weakness and Walking Slowness for the Identification of Sarcopenia in the Older Adults from Northern Brazil: A Cross-Sectional Study. 62
35954652 2022
627
Hookup experiences and feelings of regret: The effects of gender, college context, and hookup characteristics. 62
32877626 2022
628
Milk intake across adulthood and muscle strength decline from mid- to late life: the MRC National Survey of Health and Development. 62
35795912 2022
629
A Cross-Sectional Study on the Associations between Physical Activity Level, Depression, and Anxiety in Smokers and Ex-Smokers. 62
36011059 2022
630
The Transaxillary Route as a Second Access Option in TAVI Procedures: Experience of a Single Centre. 62
35886501 2022
631
Effects of Difficulty in Handling Emotions and Social Interactions on Nomophobia: Examining the Mediating Role of Feelings of Loneliness. 62
35919865 2022
632
Derivation and validation of risk prediction for posttraumatic stress symptoms following trauma exposure. 62
35775366 2022
633
A systematic review and meta-analysis of the evidence for community-based HIV testing on men's engagement in the HIV care cascade. 62
35786140 2022
634
Heat tolerance and the validity of occupational heat exposure limits in women during moderate-intensity work. 62
35259026 2022
635
Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults. 62
35893257 2022
636
Effects of sex and wet-bulb globe temperature on heart rate variability during prolonged moderate-intensity exercise: a secondary analysis. 62
35290752 2022
637
Dietary Patterns of 479 Indonesian Adults and Their Associations with Sodium and Potassium Intakes Estimated by Two 24-h Urine Collections. 62
35889861 2022
638
Change in Neuroticism and Extraversion among Pre-University Education Employees during the COVID-19 Pandemic. 62
35888616 2022
639
Branched sexuality and sexual health among Black cisgender sexual minority men in Baltimore, Maryland: an exploratory study. 62
35830487 2022
640
Thermogenic responses to different clamped skin temperatures in cold-exposed men and women. 62
35411809 2022
641
Low Cardiorespiratory Fitness, Muscular Fitness, and Flexibility Are Associated with Body Fat Distribution and Obesity Risk Using Bioelectrical Impedance in Taiwanese Adults. 62
35886714 2022
642
Comparative Effects of Co-Ingesting Whey Protein and Glucose Alone and Combined on Blood Glucose, Plasma Insulin and Glucagon Concentrations in Younger and Older Men. 62
35956288 2022
643
A Study on the Association Between Family Support and High-Risk Sexual Behavior of Elderly Men in Rural China. 62
35848123 2022
644
Preexisting Depression and Daytime Sleepiness in Women and Men. 62
34003712 2022
645
Sex Differences in Clinical Characteristics, Management Strategies, and Outcomes of STEMI With COVID-19: NACMI Registry. 62
35812987 2022
646
Association between the presence of Mycoplasma spp. and male infertility. 62
34937499 2022
647
Analgesic Effect of Alcohol Mediates the Association between Alcohol Intoxication and Deliberate Self-Harm. 62
33275544 2022
648
Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs. 62
35076310 2022
649
The incidence of insulinoma in Western Sweden between 2002 and 2019. 62
35784630 2022
650
Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review. 62
35838801 2022
651
Multi-level annotation of germline MEN1 variants of synonymous, non-synonymous and uncertain significance in Indian patients with sporadic primary hyperparathyroidism. 62
35856247 2022
652
Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms. 62
36206476 2022
653
A successfully treated Brugada syndrome presenting in ventricular fibrillation preceded by fever and concomitant hypercalcemia. 62
35936950 2022
654
Effect of Menin Deletion in Early Osteoblast Lineage on the Mineralization of an In Vitro 3D Osteoid-like Dense Collagen Gel Matrix. 62
35892371 2022
655
Hypercalcemic crisis caused by primary hyperparathyroidism in a 11-year-old boy: a rare case report and review of the literature. 62
35935565 2022
656
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. 62
35477182 2022
657
Giant prolactinoma in children and adolescents: a single-center experience and systematic review. 62
35851929 2022
658
Identification of New Molecular Biomarkers in Ovarian Cancer Using the Gene Expression Profile. 62
35807169 2022
659
Demographics of Common Compressive Neuropathies in the Upper Extremity. 62
35815639 2022
660
MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. 62
35323929 2022
661
Greater Muscular Strength Is Associated with a Lower Risk of Pulmonary Dysfunction in Individuals with Non-Alcoholic Fatty Liver Disease. 62
35887915 2022
662
Risk factors for complications after surgery for pancreatic neuroendocrine tumors. 62
35341591 2022
663
Thymoma (World Health Organization Type AB) in multiple endocrine neoplasia type 1: a case report. 62
35821790 2022
664
Analysis of 55 patients with multiple endocrine neoplasia type 1-associated insulinoma from a single center in China. 62
35698198 2022
665
Impact of parathyroidectomy on quality of life in multiple endocrine neoplasia type 1. 62
35583183 2022
666
Corrigendum to 'Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes' [Surgery 171 (2021) 77-87]. 62
35428475 2022
667
Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT. Illustrative cases and pitfalls. 62
35005879 2022
668
Zollinger Ellison Syndrome Refractory to Medical Therapy in the Setting of Multiple Endocrine Neoplasia Type I. 62
35919366 2022
669
Observational study of population genomic screening for variants associated with endocrine tumor syndromes in a large, healthcare-based cohort. 62
35668420 2022
670
Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. 62
35446370 2022
671
Insulinoma-Accurate Preoperative Localization Is the Key to Management: An Initial Experience. 62
35782810 2022
672
Case Report: Acquired collagenoma on the dorsum of the foot. 62
35368583 2022
673
Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. 62
35169281 2022
674
The Frequency of Primary Healthcare Contacts Preceding the Diagnosis of Lower-Extremity Arterial Disease: Do Women Consult General Practice Differently? 62
35806951 2022
675
Differences in Pulmonary and Extra-Pulmonary Traits between Women and Men with Chronic Obstructive Pulmonary Disease. 62
35806965 2022
676
The age-invariant role of resilience resources in emotional symptomatology. 62
33896284 2022
677
Confirmatory Factor and Measurement Invariance Analyses of the Drive for Muscularity Scale in Sexual Minority Men and Women. 62
35757789 2022
678
Dietary Plant Sterols and Phytosterol-Enriched Margarines and Their Relationship with Cardiovascular Disease among Polish Men and Women: The WOBASZ II Cross-Sectional Study. 62
35807845 2022
679
Sympathetic Nervous System Predominance in Intimate Partner Violence Perpetrators After Coping With Acute Stress. 62
33435804 2022
680
Well-Being in the Context of COVID-19 and Quality of Life in Czechia. 62
35742413 2022
681
The independent contribution of muscularity-oriented disordered eating to functional impairment and emotional distress in adult men and women. 62
35671325 2022
682
The impacts of sexual stigma on the mental health of older sexual minority men. 62
33949273 2022
683
Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. 62
35166141 2022
684
Higher Neutrophil-To-Lymphocyte Ratio Was Associated with Increased Risk of Chronic Kidney Disease in Overweight/Obese but Not Normal-Weight Individuals. 62
35805736 2022
685
Telescoping and gender differences in high-risk gambling: Loss limit behavior in a population of electronic gaming machine players. 62
35727312 2022
686
Sex Differences in Temporal Trends of Cardiovascular Health in Young US Adults. 62
35652471 2022
687
Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. 62
35638091 2022
688
Association between Gut Microbiota and Body Composition in Japanese General Population: A Focus on Gut Microbiota and Skeletal Muscle. 62
35742712 2022
689
Sex-Based Differences in Athletes Undergoing Primary Hip Arthroscopy With Labral Reconstruction: A Propensity-Matched Analysis With Minimum 2-Year Follow-up. 62
35677021 2022
690
Emotion Regulation in Context: Expressive Flexibility as a Stigma Coping Resource for Sexual Minority Men. 62
35757788 2022
691
Blood Chromium Levels and Their Association with Cardiovascular Diseases, Diabetes, and Depression: National Health and Nutrition Examination Survey (NHANES) 2015-2016. 62
35807870 2022
692
Psychiatric Comorbidity in Prurigo Nodularis and the Impact of Socioeconomic Status. 62
35783571 2022
693
Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan. 62
35689392 2022
694
Inequality and the "Universal" Gay Male Experience: Developing the Concept of Gay Essentialism. 62
35674714 2022
695
Mixed-methods findings from the Ngutulu Kagwero (agents of change) participatory comic pilot study on post-rape clinical care and sexual violence prevention with refugee youth in a humanitarian setting in Uganda. 62
35770702 2022
696
Gender and Age Differences in Performance of Over 70,000 Chinese Finishers in the Half- and Full-Marathon Events. 62
35805460 2022
697
Dispelling a Myth: Reevaluating the Predictive Validity of Rape Myth Acceptance for Likelihood of Engaging in Sexual Violence. 62
34167405 2022
698
Perceptions and Knowledge Regarding Medical Situations at the End of Life among Older Adults in Switzerland. 62
35766582 2022
699
Australian First-Year Nursing Student Knowledge and Attitudes on Pressure Injury Prevention: A Three-Year Educational Intervention Survey Study. 62
35894032 2022
700
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV. 62
35730471 2022
701
Sex Difference in Control of Low-Density Lipoprotein Cholesterol in Older Patients after Acute Coronary Syndrome. 62
35893318 2022
702
Explorative Questionnaire Study about Education with Regard to the Health of Sexual Minorities at an Austrian Medical University. 62
35700380 2022
703
The Disinhibiting Effects of Anonymity Increase Online Trolling. 62
35594292 2022
704
Prevalence of Sexual Victimization Among Female and Male College Students: A Methodological Note With Data. 62
33300396 2022
705
Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021. 62
35247311 2022
706
Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study. 62
35800039 2022
707
An essential practice summary of the new EANM guidelines for parathyroid imaging. 62
35166093 2022
708
Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. 62
34939666 2022
709
Effects of a Treadmill Workstation on Coagulation Potential. 62
35554322 2022
710
Sex differences in sympathetic neurovascular and neurohemodynamic relationships during cold pressor test. 62
35293259 2022
711
Patterns of Genital and Subjective Sexual Arousal in Cisgender Asexual Men. 62
35609125 2022
712
A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. 62
34475237 2022
713
Self-Reported Total Screen Time and Viewing Modes Are Associated with Body Dissatisfaction, Disordered Eating, and Cosmetic Surgery Intentions among Young Adults. 62
35631168 2022
714
Stress Correlates Related to Depressive Symptoms Among Young Black Men in Southern California. 62
35549937 2022
715
Associations between Internalized Weight Stigma and Visceral Adipose Tissue Status are Observed in Women but not Men. 62
35859781 2022
716
Does exogenous androgen use affect the retinal blood flow: An OCTA study in transgender men. 62
34053312 2022
717
Challenges in obtaining accurate anthropometric measures for adults with severe obesity: A community-based study. 62
35491931 2022
718
Self-objectification: Implications for physical activity in middle-aged women and men. 62
35510895 2022
719
Impact of Different Measures of Body Size on the Radiation Dose During Coronary Angiography and Percutaneous Coronary Intervention: Results from a Large Single Center Cohort. 62
35049400 2022
720
Love in the Gay World: Negotiating Intimate Relationships in Lima´s Middle-Class Gay Scene. 62
33818315 2022
721
Sex-Based Difference in the Effect of Metoprolol on Heart Rate and Bradycardia in a Population-Based Setting. 62
35743655 2022
722
Design, methods, and baseline characteristics of the Brain Injury Education, Training, and Therapy to Enhance Recovery (BETTER) feasibility study: a transitional care intervention for younger adult patients with traumatic brain injury and caregivers. 62
35174756 2022
723
Significance of Neuronal Autoantibodies in Comparison to Infectious Etiologies among Patients Presenting with Encephalitis in a Region with a High Prevalence of Infections. 62
35936609 2022
724
Study of Sexual Concordance in Men and Women with Different Typologies of Adherence to the Sexual Double Standard. 62
35281774 2022
725
Post-COVID-19 distress and unhealthy behavior. 62
35510749 2022
726
Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. 62
35666082 2022
727
Motives between the Sheets: Understanding Obligation for Sex at Midlife and Associations with Sexual and Relationship Satisfaction. 62
35608313 2022
728
Dorsal Root Ganglion Volumetry by MR Gangliography. 62
35450855 2022
729
Witnessing Parental Violence and Cyber IPV Perpetration in Hispanic Emerging Adults: The Mediating Role of Attitudes Toward IPV. 62
33246379 2022
730
Antioxidants for male subfertility. 62
35506389 2022
731
Family Supportive Supervisor Behaviors Moderate Associations between Work Stress and Exhaustion: Testing the Job Demands-Resources Model in Academic Staff at an Austrian Medical University. 62
35565163 2022
732
Sex-specific effects of cardiorespiratory fitness on age-related differences in cerebral hemodynamics. 62
35446599 2022
733
The Importance of Periodical Screening for Primary Hyperparathyroidism in a Pituitary Tumor Cohort in Searching Patients With MEN1 and Its Genetic Profile. 62
35247589 2022
734
Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors. 62
35521758 2022
735
68Ga-DOTANOC PET/CT in Multiple Endocrine Neoplasia 1 With Associated Adrenocortical Carcinoma. 62
35195585 2022
736
Menin regulates lipid deposition in mouse hepatocytes via interacting with transcription factor FoxO1. 62
35182330 2022
737
Role of 68Ga-DOTATOC PET/CT in Insulinoma According to 3 Different Contexts: A Retrospective Study. 62
35307723 2022
738
The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms. 62
35179814 2022
739
Dichotomous Roles of Men1 in Macrophages and Fibroblasts in Bleomycin-Induced Pulmonary Fibrosis. 62
35628193 2022
740
Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. 62
35734622 2022
741
Genetic Deletion of Menin in Mouse Mesenchymal Stem Cells: An Experimental and Computational Analysis. 62
35509630 2022
742
Achalasia and acromegaly: Co-incidence of these diseases or a new syndrome? 62
34282806 2022
743
Treatment response and clinical outcomes of well differentiated high grade neuroendocrine tumors to lutetium-177 DOTATATE. 62
35609558 2022
744
A rare case of insulinoma presenting with deep vein thrombosis, successfully treated with minimally invasive procedures including microwave ablation. 62
35510504 2022
745
Histone Modification on Parathyroid Tumors: A Review of Epigenetics. 62
35628190 2022
746
An Approach to a Patient With Primary Hyperparathyroidism and a Suspected Ectopic Parathyroid Adenoma. 62
35150267 2022
747
Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021). 62
35202550 2022
748
Single-incision port robot-assisted surgery for thymic carcinoid tumor resection. 62
35505364 2022
749
Multiple endocrine neoplasia type 1 involving both the liver and lung: a case report. 62
35538538 2022
750
Oral health aspects in sporadic and familial primary hyperparathyroidism. 62
35582348 2022
751
Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 Florentine database. 62
35324455 2022
752
Evaluation of risk factors, long-term outcomes, and immediate and delayed autotransplantation to minimize postsurgical hypoparathyroidism in multiple endocrine neoplasia type 1 (MEN1): A retrospective cohort study. 62
34952716 2022
753
Multiple endocrine neoplasia type 1 caused by mosaic mutation: clinical follow-up and genetic counseling? 62
35521764 2022
754
Vasoactive intestinal peptide secreting tumour: An overview. 62
35582098 2022
755
[Comparison of clinical features between sporadic pancreatic neuroendocrine tumors and those associated with multiple endocrine neoplasia type 1]. 62
35399021 2022
756
Multiple Endocrine Neoplasia Type 1 with Functional Parathyroid Cysts. 62
34645755 2022
757
Clinical Features of Pancreatic Neuroendocrine Microadenoma: A Single-Center Experience and Literature Review. 62
35699685 2022
758
Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1. 62
35454834 2022
759
Management and Long-Term Follow-Up of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Single Center Experience. 62
35407574 2022
760
Pancreatic Carcinoid Tumor in a Pediatric Patient. 62
35393387 2022
761
Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man. 62
35629143 2022
762
Nationwide Analysis of Persistent Type II Endoleak and Late Outcomes of Endovascular Abdominal Aortic Aneurysm Repair in Japan: A Propensity-Matched Analysis. 62
35209732 2022
763
Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield. 62
35026032 2022
764
Preimplantation genetic testing in patients with genetic susceptibility to cancer. 62
35415820 2022
765
Gastric neuroendocrine neoplasms: a primer for radiologists. 62
35411433 2022
766
Adrenocortical carcinoma: Pediatric aspects (Review). 62
35317446 2022
767
Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease. 62
34940846 2022
768
Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. 62
35248713 2022
769
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis. 62
34237211 2022
770
Long delay in diagnosis of a case with MEN1 due to concomitant presence of AIMAH with insulinoma: a case report and literature review. 62
35448982 2022
771
Secretin Stimulation Test and Early Diagnosis of Gastrinoma in MEN1 Syndrome: Survey on the MEN1 Florentine Database. 62
34922358 2022
772
Menin Enhances Androgen Receptor-Independent Proliferation and Migration of Prostate Cancer Cells. 62
35014621 2022
773
Mixed gangliocytoma-pituitary adenoma in MEN1 syndrome: A case report and literature review. 62
35137463 2022
774
Age, Education, and Stress Affect Ageing Males' Symptoms More than Lifestyle Does: The Wroclaw Male Study. 62
35564437 2022
775
Dimensions of couples' sexual communication, relationship satisfaction, and sexual satisfaction: A meta-analysis. 62
34968095 2022
776
Exploring factors associated with HIV secondary stigma among adolescents and young adults in Uganda: A cross-sectional study. 62
33406003 2022
777
"I Have Guys Call Me and Say 'I Can't Be the Victim of Domestic Abuse'": Exploring the Experiences of Telephone Support Providers for Male Victims of Domestic Violence and Abuse. 62
32727270 2022
778
The Metabolic Profiles of Metabolically Healthy Obese and Metabolically Unhealthy Obese South African Adults over 10 Years. 62
35564455 2022
779
Incidence, Nature, and Consequences of Oncologists' Experiences With Sexual Harassment. 62
35089804 2022
780
Physical Activity of Poles in the Care for Their Health Potential Before and During the COVID-19 Pandemic. 62
33087195 2022
781
Association between Healthy Eating Index and Mental Health in Middle-Aged Adults Based on Household Size in Korea. 62
35457558 2022
782
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. 62
35563746 2022
783
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. 62
35566604 2022
784
Effects of a Cool-Down after Supramaximal Interval Exercise on Autonomic Modulation. 62
35564802 2022
785
Validation of a Modified Version of the German Sedentary Behavior Questionnaire. 62
35627946 2022
786
Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence. 62
35266824 2022
787
Correlates of employment among men in substance use recovery: The influence of discrimination and social support. 62
34162309 2022
788
Racial and Gender Inequalities in Food, Housing, and Healthcare Insecurity Associated with Intimate Partner and Sexual Violence. 62
35404722 2022
789
The Influence of L-menthol on Time Trial Running Performance in Recreational Runners. 62
35412444 2022
790
Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study. 62
35430874 2022
791
Hibiscus sabdariffa tea affects diet-induced thermogenesis and subjective satiety responses in healthy men but not in women: a randomized crossover trial. 62
34370964 2022
792
Evaluating mental health literacy amongst US college students: a cross sectional study. 62
35471990 2022
793
Circulating Metabolome and White Matter Hyperintensities in Women and Men. 62
35050683 2022
794
HIV-positive women have higher prevalence of comorbidities and anticholinergic burden: assessment of the HIV-positive population from Menorca (Balearic Islands). 62
35473442 2022
795
Genetic polymorphisms in CYP19A1 and ESR1 are associated with serum CK activity after prolonged running in men. 62
35175101 2022
796
Gender differences in bodyweight change following COVID-19 lockdown measures in the Netherlands: a prospective longitudinal study. 62
35477883 2022
797
Psychiatric hospitalisations for people who are incarcerated, 2009-2019: An 11-year retrospective longitudinal study in France. 62
35434587 2022
798
A preliminary exploration on psychological variables related to online social network addiction. 62
35472155 2022
799
Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study. 62
35418416 2022
800
Prediction Model including Gastrocnemius Thickness for the Skeletal Muscle Mass Index in Japanese Older Adults. 62
35409723 2022
801
Parathyroid Carcinoma: a Review. 62
35462650 2022
802
Challenges with providing gender-sensitive care: exploring experiences within pediatric rehabilitation hospital. 62
32579413 2022
803
Intimate Partner Violence Predicts Posttraumatic Stress Disorder Severity Independent of Early Life and Deployment-Related Trauma in Deployed Men and Women Veterans. 62
32659158 2022
804
Gender Differences and Their Influences on T2DM Self-Management Among Spanish-Speaking Latinx Immigrants. 62
33906459 2022
805
Men's and women's endorsement of hegemonic masculinity and responses to COVID-19. 62
35274550 2022
806
Diet and Respiratory Infections: Specific or Generalized Associations? 62
35334852 2022
807
Measuring Anticipated Loss of Aging Parents: Development of the Parent Anticipatory Loss Scale. 62
34518421 2022
808
Depression and Intolerance of Uncertainty: Association with Decisional Conflict in Otolaryngology Patients. 62
34041923 2022
809
Physiological and Anthropometric Differences among Endurance, Strength and High-Intensity Functional Training Participants: A Cross-Sectional Study. 62
35302436 2022
810
Clinical Characteristics and Multimodal Imaging Findings of Central Serous Chorioretinopathy in Women versus Men. 62
35330031 2022
811
[Current status of regular exercise and influencing factors in 18-64 year old labor force population in Beijing]. 62
35345293 2022
812
Effect of Smoking on Short-term Postoperative Complications After Elective Upper Extremity Surgery. 62
32486862 2022
813
Changes in the Sexual Behavior of Partners in Each Trimester of Pregnancy in Otwock in Polish Couples. 62
35270613 2022
814
Gender Specifics of Healthy Ageing in Older Age as Seen by Women and Men (70+): A Focus Group Study. 62
35270831 2022
815
Observing the water handling in humans to resolve the role of the interstitium: preliminary results of the usability of deuterium oxide and bio-impedance analysis - a pilot analysis. 62
35072572 2022
816
Characterization and sex-related differences in the multi-location external workload profile of semiprofessional basketball players. A cross-sectional study. 62
34802390 2022
817
Effect of Age and Acute-Moderate Intensity Exercise on Biomarkers of Renal Health and Filtration. 62
35453726 2022
818
Deciphering the Microbiota and Volatile Profiles of Algerian Smen, a Traditional Fermented Butter. 62
35456786 2022
819
Why Men (Don't) Buy Sex: Purity Moralization and Perceived Harm as Constraints on Prostitution Offending. 62
33797295 2022
820
Understanding the Latent Structure of Dynamic Risk: Seeking Empirical Constraints on Theory Development Using the VRS-SO and the Theory of Dynamic Risk. 62
33813960 2022
821
Associations between dairy consumption and constipation in adults: A cross-sectional study. 62
33827333 2022
822
Accuracy of Estimated Bioimpedance Parameters with Octapolar Segmental Bioimpedance Analysis. 62
35408295 2022
823
Posture-Related Differences in Cardiovascular Function Between Young Men and Women: Study of Noninvasive Hemodynamics in Rural Malawi. 62
35195013 2022
824
Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. 62
35189691 2022
825
Molecular Engineering Super-Robust Dry/Wet Adhesive with Strong Interface Bonding and Excellent Mechanical Tolerance. 62
35230813 2022
826
Outpatient parathyroidectomy in the pediatric population: An 18-year experience. 62
33745744 2022
827
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. 62
35285002 2022
828
Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. 62
35317849 2022
829
Low Perinatal Androgens Predict Recalled Childhood Gender Nonconformity in Men. 62
35191784 2022
830
Sex-Specific Risk Factors for Short- and Long-Term Outcomes after Surgery in Patients with Infective Endocarditis. 62
35407487 2022
831
Propensity Score-Matched Comparison of Right Ventricular Strain in Women and Men Before and After Left Ventricular Assist Device Implantation. 62
35275496 2022
832
Boredom Proneness Predicts Self-Assessed Decision Errors in Sports but Is Unrelated to Risk Taking in General. 62
35329163 2022
833
Faecal haemoglobin concentrations in women and men diagnosed with colorectal cancer in a national screening programme. 62
34806935 2022
834
Old before their time: Comparisons of people with SMI and healthy older adults. 62
34323533 2022
835
Fluid Intelligence Moderates the Link Between Psychopathy and Aggression Differently for Men and Women. 62
32787489 2022
836
The Prevalence of Sexual Interest in Children and Sexually Harmful Behavior Self-Reported by Men Recruited Through an Online Crowdsourcing Platform. 62
33993798 2022
837
Sacral Insufficiency Fracture Following Short-Segment Lumbosacral Fusion: Case Series and Review of the Literature. 62
32865022 2022
838
Masculinity Barriers to Ever Completing Colorectal Cancer Screening among American Indian/Alaska Native, Black, and White Men (Ages 45-75). 62
35270762 2022
839
Intimate Partner Violence Victimization and Depressive Symptoms in Sichuan, China: Are There Gender Variations? 62
32713237 2022
840
Sex Differences between Medical Students in the Assessment of the Fear of COVID-19. 62
35329060 2022
841
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. 62
35171113 2022
842
Noninvasive Prenatal Diagnosis of a Paternally Inherited MEN1 Pathogenic Splicing Variant. 62
34897474 2022
843
Insulinoma in an adolescent female with weight loss: a case report and literature review on pediatric insulinomas. 62
35264462 2022
844
Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation. 62
35287658 2022
845
[Less-than-subtotal parathyroidectomy in MEN1-ralated primary hyperparathyroidism: a case report]. 62
35193346 2022
846
A novel MEN1 gene mutation associated with a pancreatic neuroendocrine tumor co-producing insulin and vasoactive intestinal polypeptide. 62
35297010 2022
847
Investigating the Effects of Amino Acid Variations in Human Menin. 62
35268848 2022
848
The role of menin in bone pathology. 62
35148273 2022
849
Multifunctional liposomal nanostructure-mediated siRNA/bortezomib co-delivery for SHARP1 knockdown in MLL-AF6 acute myeloid leukemia. 62
35577689 2022
850
Overview of the 2022 WHO Classification of Parathyroid Tumors. 62
35175514 2022
851
Multiple electrolyte disturbances as the presenting feature of multiple endocrine neoplasia type 1 (MEN-1). 62
35264463 2022
852
Coexistence of Renin-independent Aldosterone Secretion and Multiple Endocrine Neoplasia Type 1 Within a Family. 62
35187382 2022
853
Multiple endocrine neoplasia type 1: a new germline "homozygous" variant (c.201delC) caused by detection errors. 62
35255927 2022
854
Occult insulinoma with treatment refractory, severe hypoglycaemia in multiple endocrine neoplasia type 1 syndrome; difficulties faced during diagnosis, localization and management; a case report. 62
35296318 2022
855
The role of 18F-FDG PET/CT and single isotope 99mTc-tetrofosmin scintigraphy combined with SPECT in diagnosis of multiple endocrine neoplasia type 1 syndrome. 62
35851889 2022
856
Acromegaly caused by a GHRH-producing pancreatic neuroendocrine tumor: a rare manifestation of MEN1 syndrome. 62
35199646 2022
857
Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. 62
34560682 2022
858
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). 62
33905872 2022
859
Sex-dependent GOAL screening performance in adults at risk for obstructive sleep apnea. 62
35151621 2022
860
Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders. 62
35038313 2022
861
68 Ga-DOTATATE PET/CT imaging in endogenous hyperinsulinemic hypoglycemia: A tertiary endocrine centre experience. 62
34498757 2022
862
Single Time Frame Overview of the Genetic Changes in Conjunctival Melanoma from Intraepithelial Disease to Invasive Melanoma: A Study of 4 Exenteration Specimens Illustrating the Potential Role of Cyclin D1. 62
35356600 2022
863
MEN1 Surveillance Guidelines: Time to (Re)Think? 62
35079671 2022
864
Metastatic insulinoma presenting after bariatric surgery in a patient diagnosed with MEN1. 62
35145695 2022
865
Menin directs regionalized decidual transformation through epigenetically setting PTX3 to balance FGF and BMP signaling. 62
35194044 2022
866
Exploring the MEN1 dependent modulation of caspase 8 and caspase 3 in human pancreatic and murine embryo fibroblast cells. 62
34878630 2022
867
[Severe bone complications of primary hyperparathyroidism in a young patient with the rare verified mutation of MEN1]. 62
35262299 2022
868
Rape Myths Among University Men and Women in Vietnam: A Qualitative Study. 62
32529939 2022
869
Developing an Inclusive Conceptual Model for Preventing Violence in the Home in Humanitarian Settings: Qualitative Findings From Myanmar and the Democratic Republic of Congo. 62
32438884 2022
870
Do Sexual Minorities Face Greater Risk for Sexual Harassment, Ever and at School, in Adolescence? : Findings From a 2019 Cross-Sectional Study of U.S. Adults. 62
32571176 2022
871
Sex-Specific Aspects of Skeletal Muscle Metabolism in the Clinical Context of Intensive Care Unit-Acquired Weakness. 62
35160299 2022
872
Change in Thyroid Hormone Metabolite Concentrations Across Different Thyroid States. 62
34806412 2022
873
'Doing it in the right order': childless men's intentions regarding family formation. 62
32567408 2022
874
Associated Risk Factors with Low Back Pain in White-Collar Workers-A Cross-Sectional Study. 62
35268366 2022
875
Reference Percentiles for Bioelectrical Phase Angle in Athletes. 62
35205130 2022
876
Infertility and perceived stress: the role of identity concern in treatment-seeking men and women. 62
31903818 2022
877
Gender difference in the relationship between lipid accumulation product index and pulse pressure in nondiabetic Korean adults: The Korean National Health and Nutrition Examination Survey 2013-2014. 62
34821192 2022
878
Coercive Sexual Experiences that Include Orgasm Predict Negative Psychological, Relationship, and Sexual Outcomes. 62
35170332 2022
879
[Analysis of the current status and related factors of oral nutritional supplements intake among 18-79 years old in Beijing in 2017]. 62
35184489 2022
880
Effect of maturation on parasympathetic modulation during exercise and recovery. 62
35147067 2022
881
Food Patterns of Hospitalized Patients with Heart Failure and Their Relationship with Demographic, Economic and Clinical Factors in Sergipe, Brazil. 62
35267962 2022
882
Sensation seeking and alcohol expectancies regarding sexual aggression as moderators of the relationship between alcohol use and coercive condom use resistance intentions. 62
35175066 2022
883
Postoperative pain after endodontic treatment of necrotic teeth submitted to large apical preparation using oscillatory kinematics. 62
35173899 2022
884
Gendered Impacts of the COVID-19 Pandemic on Food Behaviors in North Africa: Cases of Egypt, Morocco, and Tunisia. 62
35206378 2022
885
Physician Perspectives on the Effect of Topical Steroid Costs on Patients and Proposed Solutions. 62
34668921 2022
886
Associations between endogenous sex hormones and FGF-23 among women and men in the Multi-Ethnic Study of Atherosclerosis. 62
35613118 2022
887
Exploring the causal role of intimate partner violence and abuse on depressive symptoms in young adults: a population-based cohort study. 62
35000596 2022
888
Psychopathological Symptoms and Personality Traits as Predictors of Problematic Smartphone Use in Different Age Groups. 62
35200272 2022
889
Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment. 62
34286350 2022
890
The fear of social stigma experienced by men: a barrier to male involvement in antenatal care in Misungwi District, rural Tanzania. 62
35039002 2022
891
Bioelectrical impedance analysis as an alternative to dual-energy x-ray absorptiometry in the assessment of fat mass and appendicular lean mass in patients with obesity. 62
34482097 2022
892
Somatosensory Cortex Repetitive Transcranial Magnetic Stimulation and Associative Sensory Stimulation of Peripheral Nerves Could Assist Motor and Sensory Recovery After Stroke. 62
35479184 2022
893
Identifying Occupation Groups for Suicide Prevention: A Statewide Data Linkage Study. 62
34989315 2022
894
Endothelial Progenitor Cell Levels and Extent of Post-prandial Lipemic Response. 62
35237643 2022
895
The Black Panther, Masculinity Barriers to Medical Care, and Colorectal Cancer Screening Intention Among Unscreened American Indian/Alaska Native, Black, and White Men. 62
35462819 2022
896
Non-Right Handedness is Associated with More Time Awake After Sleep Onset and Higher Daytime Sleepiness Than Right Handedness: Objective (Actigraphic) and Subjective Data from a Large Community Sample. 62
35547181 2022
897
A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy. 62
35035631 2022
898
Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals. 62
35155686 2022
899
Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. 62
35295598 2022
900
Influence of Peroxisome Proliferator-Activated Receptor (PPAR)-gamma Coactivator (PGC)-1 alpha gene rs8192678 polymorphism by gender on different health-related parameters in healthy young adults. 62
35936915 2022
901
The Optimal Axial Anatomical Site for a Single-Slice Area to Quantify the Total Volume of Visceral Adipose Tissue in Quantitative CT. 62
35813654 2022
902
Links between Virginity Beliefs, Negative Feelings after Virginity Loss and Sexual Performance Anxiety in a Sample of German-Speaking Heterosexual-Identified Women and Men. 62
34387143 2022
903
Content Analysis of Warning Signs Identified as Part of Crisis Response Planning in a Community Sample of Gun Owners and Non-owners. 62
35530030 2022
904
Age-, sex-, and maturity-associated variation in the phase angle after adjusting for size in adolescents. 62
35978953 2022
905
Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender. 62
35989973 2022
906
Lockdown and No Lockdown: How Norwegian and Swedish Elite Athletes Managed Preparations for Tokyo 2020 and Mental Health Challenges in the Shadow of COVID-19. 62
35982760 2022
907
Relationship of Retinal Vessel Caliber with Age-Related Macular Degeneration. 62
35957743 2022
908
Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden. 62
35968317 2022
909
The Examination of the Influence of Caffeinated Coffee Consumption on the Concentrations of Serum Prolactin and Selected Parameters of the Oxidative-Antioxidant Balance in Young Adults: A Preliminary Report. 62
35923861 2022
910
Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer. 62
35178227 2022
911
Association between the mid-upper arm circumference (MUAC) and calf circumference (CC) screening indicators of sarcopenia with the risk of pneumonia in stable patients diagnosed with schizophrenia. 62
36090356 2022
912
Effect of Coronavirus Disease (COVID-19) on Human Semen: No Evidence of Coronavirus in Semen of Patients. 62
36132075 2022
913
Behavior without beliefs: Profiles of heteronormativity and well-being among heterosexual and non-heterosexual university students in Chile. 62
36046402 2022
914
An examination of the relationship among plasma brain derived neurotropic factor, peripheral vascular function, and body composition with cognition in midlife African Americans/Black individuals. 62
36092801 2022
915
Impact of gut microbiome on dyslipidemia in japanese adults: Assessment of the Shika-machi super preventive health examination results for causal inference. 62
36118024 2022
916
Money Matters: Anticipated Expense of In-Person Obstetrics and Gynecology Fellowship Interviews Has Greater Impact for Underrepresented in Medicine and Women Applicants. 62
36000016 2022
917
Establishment of Multiple Parameter Reference Intervals for Different Age Groups in Qingdao, China. 62
35310179 2022
918
Gender Differences in Transdiagnostic Predictors of Problematic Alcohol Consumption in a Large Sample of College Students in Ecuador. 62
35282216 2022
919
Reliability and Validity of the Urdu Version of Psychosomatic Symptoms Scale in Pakistani Patients. 62
35478754 2022
920
[Association between sleep duration and activity of daily living in the elderly aged 65 years and older in China]. 62
35012298 2022
921
Violence and posttraumatic change (PTC). 62
35084917 2022
922
Does COVID-19 psychological fatigue exist? Results of three online cross-sectional studies conducted in Spain from April 2020 to March 2021. 62
35392585 2022
923
The Influence of an Acute Bout of Aerobic Exercise on Vascular Endothelial Function in Moderate Stages of Chronic Kidney Disease. 62
35054484 2022
924
Optical Coherence Tomography Angiography in Healthy Adult Subjects: Normative Values, Frequency, and Impact of Artifacts. 62
35295961 2022
925
An Earlier First Meal Timing Associates with Weight Loss Effectiveness in A 12-Week Weight Loss Support Program. 62
35057430 2022
926
Body composition and cardiorespiratory fitness in overweight or obese people post COVID-19: A comparative study. 62
36213222 2022
927
Genome-Wide Association Mapping of Hulless Barely Phenotypes in Drought Environment. 62
35812943 2022
928
Relations With the Educational Community and Transformative Beliefs Against Gender-Based Violence as Preventive Factors of Sexual Violence in Secondary Education. 62
32253970 2022
929
Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan. 62
36249252 2022
930
Alcohol consumption and atrial fibrillation risk: An updated dose-response meta-analysis of over 10 million participants. 62
36247447 2022
931
Analysis of diastolic left ventricular wall shear stress in normal people of different age groups. 62
36211550 2022
932
Mindfulness for Reducing Minority Stress and Promoting Health Among Sexual Minority Men: Uncovering Intervention Principles and Techniques. 62